

## CURRICULUM VITAE

**Mariana P. Socal, M.D., M.Sc., M.P.P., Ph.D.**

### PERSONAL DATA

#### *Home Address*

9803 Holmhurst Road  
Bethesda, MD, 20817  
Phone: (609) 865-0766

#### *Business Address*

Department of Health Policy and Management  
Johns Hopkins Bloomberg School of Public Health  
615 N Wolfe Street, Suite W7503D  
Baltimore, MD, 20205  
E-mail: msocal1@jhu.edu

### EDUCATION AND TRAINING

**Johns Hopkins Bloomberg School of Public Health**, Baltimore, MD  
Ph.D., Health Systems, Department of International Health, 2017

**Princeton University**, Princeton, NJ  
M.P.P., Public Policy, 2010

**Universidade Federal do Rio Grande do Sul**, Porto Alegre-RS, Brazil  
M.Sc., Medical Sciences, 2008

**Hospital de Clínicas de Porto Alegre**, Porto Alegre-RS, Brazil  
Residency in Neurology, 2004

**Universidade Federal do Rio Grande do Sul**, Porto Alegre-RS, Brazil  
M.D., Doctor of Medicine, 2000

#### *Medical Board or Other Certification*

**Conselho Regional de Medicina**, Rio Grande do Sul State, Brazil  
Neurologist, 2004

**Conselho Regional de Medicina**, Rio Grande do Sul State, Brazil  
Doctor of Medicine, 2000

#### *Additional Training*

Johns Hopkins Bloomberg School of Public Health Leadership Development Program, 2023-2024  
Johns Hopkins University Preparing for Future Faculty Teaching Academy, 2015-2016  
Harvard Business School Value-Based Health Care Delivery Intensive Seminar, 2010

## PROFESSIONAL EXPERIENCE

### *Current Faculty Position*

**Associate Professor, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, September 2023 – present**  
*Conducting research and policy activities on pharmaceutical pricing and accessibility; teaching and mentoring graduate students in Health Policy and Management.*

**Associate Scientist, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, February 2021 – August 2023**

**Assistant Scientist, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, April 2017 – January 2021**

**Affiliated Faculty Member, Roger C. Lipitz Center for Integrated Health Care, Johns Hopkins Bloomberg School of Public Health, 2018 – present**

**Affiliated Faculty Member, Johns Hopkins Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, 2017 – present**

### *Relevant Practice Positions*

**Research Assistant, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 2016-2017**  
*Conduct research on pharmaceutical pricing for the Johns Hopkins Drug Access and Affordability Initiative.*

**Research Assistant, Department of International Health, Johns Hopkins Bloomberg School of Public Health, 2014-2016**  
*Deliver training and conduct literature review on strengthening health systems in El Salvador. Deliver training on essential public health functions in Angola.*

**Research Assistant, JHPIEGO, 2014-2014**  
*Deliver training on essential public health functions in Mozambique.*

**Research Assistant, Johns Hopkins International Vaccine Access Center, 2011-2012**  
*Conduct literature review on vaccine cost and effectiveness.*

**Research Assistant, Princeton University Center for Health and Wellbeing, 2010-2011**  
*Conduct data collection and analysis on judicialization of health in Brazil.*

**Consultant, Brazilian Health Technology Assessment Network, 2011-2013**  
*Draft health technology assessment reports in adult Neurology.*

**Consultant, Brazilian Ministry of Health, 2009-2010**

*Draft national therapeutic guidelines on the use of botulinum toxin.*

**Research Fellow, Hospital de Clínicas de Porto Alegre, Brazil, 2008 - 2009**

*Conduct data collection and analysis on Parkinson's disease.*

**Medical Advisor, State of Rio Grande do Sul's General Attorney's Office, Brazil, 2007-2009**

*Provide assistance for state attorneys in responding to legal claims for access to high-cost Neurologic drugs in and out of the state's and the national drug formulary.*

**Pharmaceutical Policy Advisor, Rio Grande do Sul Health Secretariat, Brazil, 2005-2008**

*Provide assistance for state policy-makers in drafting the state drug formulary for Neurologic conditions. Review patient requests for on-formulary Neurologic drugs.*

**Attending Physician, Hospital Moinhos de Vento, Porto Alegre, Brazil, 2007-2012**

*Provide inpatient care in neurology, including emergency and critical care.*

**Attending Physician, UNIMED Medical Cooperative, Brazil, 2007-2012**

*Provide outpatient and inpatient care in adult Neurology.*

**Attending Physician, Instituto de Previdência do Rio Grande do Sul, Brazil, 2006-2012**

*Provide outpatient care in adult Neurology.*

**Instructor, Medical Residency Program, Hospital Luterano da ULBRA, Brazil, 2005-2008**

*Provide inpatient care in neurology, including emergency and critical care. Supervise medical residents training in Internal Medicine.*

**Attending Physician, Hospital Luterano da ULBRA, Brazil, 2004-2008**

*Provide inpatient care in neurology, including emergency and critical care.*

## **PROFESSIONAL ACTIVITIES**

### **Society Membership**

Member, Academy Health, 2024- current

Member, Academy Health, 2019 – 2021

Member, Association for Public Policy Analysis and Management, 2018-2019

Member, International Society of Pharmacoeconomics and Outcomes Research, 2018-2019

Member, International Society of Pharmacoepidemiology (ISPE), 2017-2018; 2013-2015

Member, Health Systems Global (HSG), 2016-2017

Member, Health Technology Assessment International (HTAi), 2007-2012

### **Consultations/Other Activities**

**Consultant, California Department of Health Care Access and Information (HCAI),**

**Jan 2020-present**

CalRx California Generic Drugs Initiative

Role: ongoing consultation

**Stakeholder Participant – Organization for Economic Cooperation and Development (OECD), Nov 19, 2024.**

Study: Assessing the Impact of Advertising Regulations on Biosimilar Uptake.

Role: invited expert. Shared expertise and perspectives on biosimilar uptake in the USA.

**Reviewer, RAND Corporation, August 2023, December 2023, September 2024**

Role: Peer-reviewer of RAND Corporation reports entitled: “Comparing New Prescription Drug Availability and Launch Timing in the United States and Other OECD Countries;” “Prescription Drug Prices, Rebates, and Insurance Premiums;” and “Option Year 2 Validation Report: Assessing the Accuracy, Consistency, and Generalizability of 2020-2022 RxDC Data (PR-A1820-11).”

**Stakeholder Participant, Reagan-Udall Foundation for the FDA, July 2024**

Report: Improving Access to Publicly Available FDA Information

Role: shared expertise and perspectives on using FDA data as a researcher

**Expert Witness, State of Alaska/Beasley Allen Law Firm, 2023-2024**

Role: expert consultant, prepared research on prescription drugs with potentially unjustified price increases to support litigation between the state of Alaska and pharmacy benefit managers (PBMs)

**Member, World Health Organization (WHO) Technical Advisory Group on Pricing Policies for Medicines, July 2023-present**

Role: technical advisor

**Expert Panelist, National Academies of Science, Engineering and Medicine (NASEM), October 24 and 25, 2022**

Stakeholder Meeting "Building Resilience into the Nation's Medical Product Supply Chains"

Role: technical expert on panel to provide recommendations for the Office of the Assistant Secretary for Preparedness and Response (ASPR) of the U.S. Department of Health and Human Services (HHS) on ways to strengthen the US pharmaceutical supply chain.

**Technical Expert, RAND Corporation, August 04, 2022**

Technical Expert Panel - Prescription Drug Prices, Rebates, and Insurance Premiums

Role: technical expert on panel to provide guidance for the Office of the Assistant Secretary of Planning and Evaluation (ASPE) of the Department of Health and Human Services (HHS).

**Policy Expert, Gary and Mary West Health Policy Center, Inc., 2019 - 2022**

Policy expert serving on the Council for Informed Drug Spending Analysis (CIDS).

Role: ongoing consultation

**Expert Reviewer, Texas A&M Cross-Border Threat Screening and Supply Chain Defense - A Department of Homeland Security Center of Excellence, September 2021**

Project: Call for proposals for research on the US pharmaceutical supply chain  
Role: reviewer of proposal workplans submitted to CBTS for scientific merit

**Consultant, National Academies of Science, Education, and Medicine, July-October 2020**

Project on wasteful Spending on Medicare Part B drugs led by Dr. Aditi Sen  
Role: medical consultant

**Invited Participation**

2024

Invited Panelist. Center for Strategic and International Studies (CSIS) – Roundtable: “Strengthening North American Pharmaceutical Supply Chains.” Web-based event, November 19, 2024.

Invited Panelist. Alliance for Patient Access (AfPA) National Policy & Advocacy Summit – Panel: “Pressure on Patients.” Washington, DC, September 24, 2024.

Keynote Speaker. University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences hosts Annual Research Retreat. Keystone, CO. August 01, 2024.

Invited Panelist. Johns Hopkins Bloomberg School of Public Health’s Master of Public Health Program - Public Health Policy Course. Panel: Universal Health Coverage in the United States: Challenges and Potential Solutions. Baltimore, MD. August 20, 2024.

Invited Panelist. Advocacy Action Lab. Johns Hopkins University Lerner Center for Public Health Advocacy. Panel: Leveraging advocacy in public health work. Washington, DC. June 06, 2024.

Invited Panelist. Robert Wood Johnson Health Policy Research Scholars Program. Panel: Advancing Policy Post-Graduation. Online event. May 15, 2024.

Invited Speaker. Summit on Cancer Health Disparities. Binaytra Foundation. Panel: Drug Shortages. Seattle, WA. April 26-28, 2024.

Invited Discussant. JHSPH Latino Public Health Network. Panel: High Impact Research: An Editor’s Perspective. Presenter: Dr. Taissa Vila, PhD, Editor-in-Chief, The Lancet Regional Health Americas. Baltimore, MD. March 11, 2024.

Invited Panelist. The Hill. Prescribing PBM reform, accelerating transparency with bipartisan action. Washington, DC. March 06, 2024.

Invited Speaker, Georgetown University. Supply Chain and Health Care Coverage. Washington, DC. February 28, 2024.

Invited Speaker. National Association of Medicaid Directors' policy meeting. Web-based. February 12, 2024.

Invited Speaker, National Coalition for Cancer Survivorship (NCCS) Cancer Policy Roundtable Highlights. Online event. January 17, 2024.

Invited Speaker, INOVA Fairfax Hospital Bedside to Community Series. Lecture: Pharmaceutical Pricing and Policy. Fairfax, Virginia. January 10, 2024.

## 2023

Invited speaker, National Coalition for Cancer Survivorship (NCCS) Cancer Policy Roundtable, Panel: Inflation Reduction Act Implementation. Washington, DC, November 16, 2023.

Invited speaker, Maryland State of Reform Health Policy Conference. Panel: "Methods to Lower the Cost of Drugs" Baltimore, MD – June 14, 2023

Invited speaker, National Conference for State Legislatures. Prescription Drug Peer Learning Group for State Legislators. Panels: "Insulin Affordability: What's next?" and "Pharmacy Benefit Managers: Caught in the Middle." Portland, Oregon – June 21, 2023

Invited speaker, Health Canada, Office of Pharmaceuticals Management Strategies (Strategic Policy Branch) Expert Speaker Series. Lecture: Pharmaceutical Supply Chains. Online event. June 20, 2023.

Invited speaker, Society for Health Policy Young Professionals. Panel: Inflation Reduction Act – Novel Perspectives and Career Opportunities. Washington, DC. May 11, 2023.

Invited speaker, Alaska Pharmacist Association's Continued Education program. Lecture: "Prescription drug pricing and the role of PBMs." Online event – March 31, 2023.

Invited speaker. Johns Hopkins Hospital Pediatric Intensive Care Unit's Health Policy & Equity Seminar Series. Lecture: "Prescription drug pricing and policy." Baltimore MD - March 31, 2023.

## 2022

Invited speaker, National Association of Medicaid Directors. Fall Conference. Panel: "Pharmaceutical Policy" Washington, DC – November 15, 2022

Invited expert panelist, National Academies of Science, Engineering and Medicine (NASEM) Stakeholder Meeting "Building Resilience into the Nation's Medical Product Supply Chains" – web-based event – October 24 and 25, 2022

Invited speaker, National Conference for State Legislatures. Achieving Affordable Quality Health Care Systems: Health Legislative Staff Seminar. Panel: "State Approaches to Prescription Drug Affordability" Atlanta, Georgia – October 12, 2022

Invited Speaker, US Food and Drug Administration. “Manufacturer-Sponsored Drug Coupons Support Insulin Product Line Extensions” Bethesda, MD – August 03, 2022

Invited speaker, University of Pennsylvania Perelman School of Medicine Immersive Advocacy Summer Course- Panel: “Expert Panel: Prescription Drug Affordability Board Legislation” Online Event – July 12, 2022

Invited speaker, Endpoint News - Panel: “Revamping the FDA's prized accelerated approvals” Online event – June 21, 2022

Invited speaker, National Conference for State Legislatures State Policy Seminar: Levers to Address Health Costs- Panel: “Prescription Drugs and Creating Competition” Denver, Colorado – June 06, 2022

Invited speaker, Maryland State of Reform Health Policy Conference. Panel: “Pharmacy: Balancing Access and Costs” Baltimore, MD – May 04, 2022

Invited speaker, U.S. Senator Ben Cardin Facebook Live Panel: “High Price of Prescription Drugs: Taking Action to Lower Costs” Online Event – March 18, 2022

2021

Invited speaker, Congressional Hispanic Caucus Institute Fall Summit “The Future of Accessible Medicine” – November 15, 2021

Invited speaker, Doctors for America webinar: “Lunch & Learn – Myths & Facts of Drug Pricing Proposals” – September 28, 2021

Invited Speaker, University of Pennsylvania Leonard Davis Institute of Health Economics webinar: “Drug Pricing: Policy and Politics”- September 17, 2021

### **Program Development**

Founding member, Dystonia Reference Center, State Health Secretariat of Rio Grande do Sul, Brazil, 2005-2008. Role: attending physician and assistant manager

### **EDITORIAL ACTIVITIES**

#### **Peer Reviewer for:**

*The New England Journal of Medicine, Health Affairs, JAMA, JAMA Internal Medicine, JAMA Oncology, Annals of Internal Medicine, The Millbank Quarterly, Journal of General Internal Medicine, American Journal of Managed Care, Value in Health, Journal of The Comprehensive Cancer Care Network, Journal of Aging and Health, International Journal for Equity in Health, American Journal of Accountable Care, Health Promotion and Practice, Health Education Research, Pan American Journal of Public Health, Heart Journal.*

### **HONORS AND AWARDS**

*Honors*

- Outstanding Teaching Recognition, Johns Hopkins Bloomberg School of Public Health, 2024  
Course: U.S. Pharmaceutical Policy; U.S. Pharmaceutical Policy Summer Institute
- Outstanding Teaching Recognition, Johns Hopkins Bloomberg School of Public Health, 2023  
Course: U.S. Pharmaceutical Policy
- Outstanding Teaching Recognition, Johns Hopkins Bloomberg School of Public Health, 2022  
Course: U.S. Pharmaceutical Policy
- Outstanding Teaching Recognition, Johns Hopkins Bloomberg School of Public Health, 2021  
Course: U.S. Pharmaceutical Policy
- Outstanding Teaching Recognition, Johns Hopkins Bloomberg School of Public Health, 2020  
Course: U.S. Pharmaceutical Policy
- Outstanding Teaching Recognition, Johns Hopkins Bloomberg School of Public Health, 2019  
Course: U.S. Pharmaceutical Policy
- Distinguished Teaching, Universidade Luterana do Brasil, 2009
- Distinguished Teaching, Universidade Luterana do Brasil, 2008
- Baccalaureate Speaker, Class of Medical School Graduates, Universidade Luterana do Brasil, 2008

*Awards*

- Golden Apple Award, Johns Hopkins Bloomberg School of Public Health, 2022
- Public Health Practice Award, Faculty, Johns Hopkins Bloomberg School of Public Health, 2022
- David and Elinor Bodian Scholarship, Johns Hopkins Bloomberg School of Public Health, 2016
- Henry K. and Lola Beye Scholarship, Johns Hopkins Bloomberg School of Public Health, 2016
- Teaching-As-Research Fellowship, Johns Hopkins Center for Educational Resources, 2015
- Gordis Teaching Fellowship, Johns Hopkins Krieger School of Arts and Sciences, 2015
- Gordis Teaching Fellowship, Johns Hopkins Krieger School of Arts and Sciences, 2014
- Research Fellowship, Council for Scientific and Technological Development (CNPq), Brazil 2009
- Research Fellowship, Princeton University Grand Challenges Initiative & Ford Foundation, 2008
- Scientific Research Training Program, National Council for Scientific and Technological Development (CNPq), Brazil, 2000

**PUBLICATIONS**

*Original Articles in Peer-Reviewed Journals*

1. Levy JF, **Socal MP**, Ballreich JM. Strategic Manufacturer Response to the Medicaid Rebate Cap Removal. *JAMA Health Forum*. 2024 Nov 1;5(11):e243624.
2. Mouslim MC, **Socal MP**, Trujillo AJ. Dynamics of biological markets with multiple biosimilar competitors in the United States. *Expert Opin Biol Ther*. 2024 Oct 9:1-8. doi: 10.1080/14712598.2024.2412648. Online ahead of print. PMID: 39378044
3. Plummer E, **Socal MP**, Bai G. Estimation of Tax Benefit of US Nonprofit Hospitals. *JAMA*. 2024 Sep 26:e2413413. doi: 10.1001/jama.2024.13413.
4. Wang Y, Kang SY, **Socal MP**, Dusetzina SB. Manufacturer-sponsored drug coupon use and drug-switching behavior among patients with type 2 diabetes. *J Manag Care Spec Pharm*. 2024 Sep;30(9):903-907.



5. Odouard IC, Ballreich J, Lee B, **Socal MP**. Clinical Evidence Supporting FDA Approval of Gene and RNA Therapies for Rare Inherited Conditions. *Paediatr Drugs*. 2024 Aug 5. doi: 10.1007/s40272-024-00645-7.
6. Odouard I, Ballreich J, **Socal MP**. Medicaid Spending and Utilization on Gene and RNA Therapies for rare inherited conditions. *Health Aff Sch*. 2024 Apr 26;2(5):qxae051.
7. **Socal MP**, Crane MA, Anderson GF. Global production of active pharmaceutical ingredients for US generic drugs experiencing shortages. *JAMA*. Published online April 29, 2024. doi:10.1001/jama.2024.5296
8. **Socal MP**, Sharfstein J. Drug Shortages: A Study in Complexity. *A JAMA Netw Open* 2024;7(4):e244168. doi: 10.1001/jamanetworkopen.2024.4168.
9. Yang YT, **Socal M**, Bennett CL. Addressing the Drug-Shortage Crisis in Oncology. *JAMA Oncol*. 2024 Jan 4. doi: 10.1001/jamaoncol.2023.5722.
10. Liu A, Xuan A, **Socal M**, Anderson G, Anderson KE. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019. *J Manag Care Spec Pharm*. 2024 Jan;30(1):15-21.
11. **Socal MP**, Wang Y, Plummer E, Anderson GF, Bai G. Spending on Dual Over-the-Counter and Prescription Drugs in the Medicare Part D Program. *JAMA*. 2024 Jan 2;331(1):72-75.
12. Costin J, Mouslim MC, **Socal MP**, Trujillo A. Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates. *Pharmacoecon Open*. 2024 Jan;8(1):115-118.
13. Ballreich J, Kim HS, **Socal M**. Pediatric Drugs, Accelerated Approval, and Prospects for Reform. *Paediatr Drugs*. 2024 Jan;26(1):5-8.
14. **Socal MP**, Odouard IC, Kharrazi H. Ownership and Interoperability Challenges of Alzheimer Monoclonal Antibody Registries. *JAMA Neurol*. 2024 Feb 1;81(2):109-110.
15. Odouard IC, **Socal MP**, Anderson GF. Role of Registries in Medicare Coverage of New Alzheimer Disease Drugs. *JAMA*. 2023 Oct 10;330(14):1331-1332.
16. **Socal MP**, Bai G. Insulins and the Evolving Landscape of U.S. Prescription Drug Pricing. *Ann Intern Med*. 2023 Sep;176(9):1259-1260.
17. **Socal MP**. Increasing Private Payer and Medicare Coverage of Circulating Tumor DNA Tests: What's at Stake? *J Natl Compr Canc Netw*. 2023 Jun;21(6):685-686.
18. Anderson KE, DiStefano MJ, Liu A, Mattingly TJ 2nd, **Socal MP**, Anderson GF. Incorporating Added Therapeutic Benefit and Domestic Reference Pricing Into Medicare Payment for Expensive Part B Drugs. *Value Health*. 2023 Sep;26(9):1381-1388.
19. Zhang M, Zucatti KP, Teixeira PP, Spiazzi BF, Correia PE, Wayerbacher LF, **Socal MP**, Boyko EJ, Colpani V, Gerchman F. Response to Letter to the Editor from Stumpf et al.: Cancer Outcomes Among Prediabetes and Type 2 Diabetes Populations With Dietary and Physical Activity-based Lifestyle Interventions. *J Clin Endocrinol Metab*. 2023 May 12:dgad266. doi: 10.1210/clinem/dgad266.
20. Anderson KE, Xuan A, Anderson GF, **Socal MP**. Estimating Changes in Medicare Part D and Commercial Insurer Insulin Spending Amid Planned State-Led Biosimilar Insulin Production in California. *JAMA Intern Med*. 2023 Jul 1;183(7):734-735.
21. Zhang M, Zucatti KP, Teixeira PP, Correia PE, Wayerbacher LF, Spiazzi BF, **Socal MP**, Boyko EJ, Colpani V, Gerchman F. Cancer outcomes among prediabetes and type 2 diabetes populations with dietary and physical activity-based lifestyle interventions: A systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2023 Mar 3:dgad123.

22. Ballreich J, **Socal M**, Bennett CL, Xuan A, Trujillo A, Anderson GF. Accelerated approval drug labels often lack information for clinical decision making. *Pharmacotherapy*. 2023 Apr;43(4):300-304.
23. **Socal MP**, Ahn K, Greene JA, Anderson GF. Competition and vulnerabilities in the global supply chain for U.S. generic active pharmaceutical ingredients. *Health Aff (Millwood)*. 2023 Mar;42(3):407-415.
24. **Socal MP**, Estus E, Long J, Crane MA, Pegany V, Anderson GF. Developing Prioritization Criteria to Identify Target Drugs for CalRx the California Generic Drugs Initiative. *Value Health*. 2022 Nov 12:S1098-3015(22): 4734-9.
25. **Socal MP**, Pegany V, Ghaly M. When States Step Up: California and the Case for State-Led Insulin Manufacturing. *Ann Intern Med*. 2022 Nov 15. doi: 10.7326/M22-2339.
26. Mouslim MC, Rashidi ES, Levy JF, **Socal MP**, Trujillo AJ. The price paradox of biosimilar-like long-acting insulin. *Am J Manag Care*. 2022 Nov 1;28(11):e405-e410
27. **Socal MP**, Cordeiro T, Anderson GF, Bai G. Estimating Savings Opportunities From Therapeutic Substitutions of High-Cost Generic Medications. *JAMA Netw Open*. 2022 Nov 1;5(11):e2239868
28. Ballreich J, **Socal M**, Anderson GF. Anticipating Reforms to the Prescription Drug User Fees Act. *JAMA Netw Open*. 2022 Nov 1;5(11):e2239341.
29. **Socal MP**, Ortiz JA, Garcia F, Pingret-Kipman D. Pharmaceutical regulation, pricing, coverage and policy reform in the United States of America. *Rev Bras Farm Hosp Serv Saude*. 2022;13(3):0847.
30. Mattingly TJ 2nd, Lewis M, **Socal MP**, Bai G. State-level policy efforts to regulate pharmacy benefit managers (PBMs). *Res Social Adm Pharm*. 2022 Jul 31:S1551-7411(22)00264-9.
31. Trujillo AJ, Gutierrez JC, Garcia Morales EE, **Socal M**, Ballreich J, Anderson G. Trajectories of prices in generic drug markets: what can we infer from looking at trajectories rather than average prices? *Health Econ Rev*. 2022 Jul 11;12(1):37.
32. Plummer E, **Socal MP**, Ballreich JM, Bai G, Anderson GF. Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019. *JAMA Health Forum*. 2022;3(5):e220888
33. Ballreich J, **Socal M**, Bennett CL, Schoen MW, Trujillo A, Xuan A, Anderson G. Medicare Spending on Drugs With Accelerated Approval. *Ann Intern Med*. 2022 May 24. doi: 10.7326/M21-4442.
34. Garcia FL, **Socal M**. Impacts of the 2017 Brazilian National Primary Care Policy on public primary health care in Rio de Janeiro, Brazil. *Cad Saude Publica*. 2022 May30; 38(5):e00219421.
35. Duarte AC, Spiazzi BF, Merello EN, Amazarray CR, Sulzbach de Andrade L, **Socal MP**, Trujillo AJ, Brietzke E, Colpani V, Gerchman F. Misinformation in nutrition through the case of coconut oil: An online before-and-after study. *Nutr Metab Cardiovasc Dis*. 2022 Jun;32(6):1375-1384.
36. **Socal MP**, Liu A, Anderson GF. Measuring and Mitigating Gender-Based Disparities in Earning Potential in Academic Medicine. *JAMA Netw Open*. 2022 Feb 1;5(2):e220074

37. DiStefano MJ, Kang SY, **Social MP**, Anderson GF. Innovation in the United States Health-Care System's Organization and Delivery. SPP Research Paper - University of Calgary The School of Public Policy Publications. January 2022 Volume 15:2 pp. 1-28  
<http://dx.doi.org/10.11575/sppp.v15i1.74116>
38. **Social MP**, Bai G. Bipartisan Federal Legislation to Address Insulin Access and Affordability. *Diabetes Spectr.* 2021 Nov;34(4):394-398.
39. **Social MP**, Bai G, Cordeiro T, Anderson GF. Association Between Waste-Free Formularies and Prescription Drug Spending Among Self-insured Employers. *JAMA Netw Open.* 2021 Oct 1;4(10):e2131486.
40. Bennett CL, Focosi D, **Social MP**, Bian JC, Nabhan C, Hrushesky WJ, Bennett AC, Schoen MW, Berger JR, Armitage JO; Southern Network on Adverse Reactions. Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. *Lancet Haematol.* 2021 Aug;8(8):e593-e604.
41. Levy J, Chowdhury ZM, **Social MP**, Trujillo AJ. Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market. *JAMA Intern Med.* 2021 Jun 28. doi: 10.1001/jamainternmed.2021.2769.
42. Fraker JH, **Social MP**. Manufacturer-Sponsored Cost-Sharing Programs for Insulin: Are Patients Getting the Help They Need? *J Gen Intern Med.* 2021 May;37(6):1561-1564.
43. Wormser B, **Social MP**, Anderson G. Variability of COPD inhaler coverage in Medicare Part D. *Am J Manag Care.* 2021 May;27(5):187-193. doi: 10.37765/ajmc.2021.88632.
44. **Social MP**, Bai G, Anderson GF. Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program. *JAMA Netw Open.* 2021;4(3):e210483.
45. **Social MP**, Anderson GF. The Role of Advance Purchasing Commitments in Government Drug Price Negotiations: Lessons From the COVID-19 Response. *Am J Public Health.* 2021 Apr;111(4):652-657.
46. **Social MP**, Sharfstein JM, Greene JA. The Pandemic and the Supply Chain: Gaps in Pharmaceutical Production and Distribution. *Am J Public Health.* 2021 Apr;111(4):635-639.
47. **Social MP**, Ezebilo I, Bai G, Anderson GF. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab. *Am J Health Syst Pharm.* 2020 Dec 8;zxaa376.
48. Padula WV, Parasrampur S, **Social MP**, Conti RM, Anderson GF. Reply to Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US". *Pharmacoeconomics.* 2020 Dec;38(12):1375-1376
49. **Social MP**, Parasrampur S, Anderson GF. Modifying the Criteria for Granting Orphan Drug Market Exclusivity. *Value In Health.* September 28, 2020 <https://doi.org/10.1016/j.jval.2020.08.004>
50. Dalpoas SE, **Social MP**, Proctor C, Shermock KM. Barriers to biosimilar utilization in the United States. *Am J Health Syst Pharm.* 2020 Oct 22; zxaa297.doi: 10.1093/ajhp/zxaa297. [Online ahead of print].
51. Padula WV, Parasrampur S, **Social MP**, Conti RM, Anderson GF. Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US.

- Pharmacoeconomics. 2020 Oct; 38(10):1115-1121.
52. **Socal MP**, Garrett JB, Tayler WB, Bai G, Anderson GF. Naming Convention, Interchangeability, and Patient Interest in Biosimilars. *Diabetes Spectr*. 2020 Aug;33(3):273-279. doi: 10.2337/ds19-0065.
  53. **Socal MP**, Sharfstein J, Greene JA. Critical Drugs for Critical Care: Protecting the US Pharmaceutical Supply in a Time of Crisis. *American Journal of Public Health*. 2020 Sept; 110(9): 1346–1347
  54. **Socal MP**. PatientNarratives: a Tool for People-Centered Health Systems Education. *Medical Sciences Educator*. July 2020. DOI: 10.1007/s40670-020-01030-y.
  55. **Socal MP**, Greene JA. Interchangeable Insulins - New Pathways for Safe, Effective, Affordable Diabetes Therapy. *N Engl J Med*. 2020 Mar 12;382(11):981-983.
  56. **Socal MP**, Anderson KE, Sen A, Bai G, Anderson GF. Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim. *Value Health*. 2020 Apr;23(4):481-486.
  57. **Socal MP**, Anderson GF Older Americans' Preferences Between Lower Drug Prices and Prescription Drug Plan Choice, 2019. *Am J Public Health*. 2020 Mar;110(3):354-356.
  58. **Socal MP**, Amon JJ, Biehl J. Right-to-Medicines Litigation and Universal Health Coverage: Institutional Determinants of the Judicialization of Health in Brazil. *Health and Human Rights Journal*, 2020 Jun; 22(1): 221–235.
  59. Medeiros MS, Reddy SP, **Socal MP**, Schumacher-Schuh A, Rieder CRM. Occupational pesticide exposure and the risk of death in patients with Parkinson’s disease: an observational study in southern Brazil. *Environmental Health* 2020; 19: 68. <https://doi.org/10.1186/s12940-020-00624-8>
  60. Kang SY, Bai G, DiStefano MJ, **Socal MP**, Yehia F, Anderson GF. Comparative Approaches to Drug Pricing. *Annu Rev Public Health*. 2020 Apr 2;41:499-512
  61. Humbyrd CJ, Wu SS, Trujillo AJ, **Socal MP**, Anderson GF. Patient Selection After Mandatory Bundled Payments for Hip and Knee Replacement: Limited Evidence of Lemon-Dropping or Cherry-Picking. *J Bone Joint Surg Am*. 2020 Feb 19;102(4):325-331.
  62. Kang SY, **Socal MP**, Bai G, Anderson GF. Off-Label Coverage of High-Cost Drugs by Independent Charity Patient Assistance Programs. *J Gen Intern Med*. 2020 Feb 24. doi: 10.1007/s11606-020-05682-9. Online ahead of print.
  63. Reddy SP, **Socal MP**, Rieder CRM, Schumacher-Schuh AF. Parkinson's disease-associated dyskinesia in countries with low access to levodopa-sparing regimens. *Mov Disord*. 2019 Dec;34(12):1929-1930.
  64. **Socal MP**, Bai G, Anderson GF. Favorable Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available. *JAMA Intern Med*. 2019 Jun 1;179(6):832-833.
  65. Levin J, Ballreich J, **Socal M**, Bai G, Anderson G. Consolidated Drug Purchasing Across Federal Agencies: A Policy to Decrease Cost Sharing for Medicare Beneficiaries. *Journal of Health Care Finance*, Summer 2019.

[https://pdfs.semanticscholar.org/b117/08e01714d11cd37c2f2c298c7b407b147b90.pdf?\\_ga=2.248090692.275773372.1579634144-1257255886.1579634144](https://pdfs.semanticscholar.org/b117/08e01714d11cd37c2f2c298c7b407b147b90.pdf?_ga=2.248090692.275773372.1579634144-1257255886.1579634144)

66. Kang SY, DiStefano MJ, **Social MP**, Anderson GF. Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other Countries. *Health Aff (Millwood)*. 2019 May;38(5):804-811.
67. Garrett JB, Tayler WB, Bai G, **Social MP**, Trujillo AJ, Anderson GF. Consumer Responses to Price Disclosure in Direct-to-Consumer Pharmaceutical Advertising. *JAMA Intern Med*. 2019 Jan 22.
68. Biehl J, **Social MP**, Gauri V, Diniz D, Medeiros M, Rondon G, Amon JJ. Judicialization 2.0: Understanding right-to-health litigation in real time. *Glob Public Health*. 2018 May 21:1-10.
69. Karas L, Shermock K, Proctor C, **Social MP**, Anderson G. Limited Distribution Networks Stifle Competition in the Generic and Biosimilar Drug Industries. *The American Journal of Managed Care*. 2018 Apr 1;24(4):e122-e127. Accepted for publication.
70. **Social MP**, Trujillo AJ. Links Between Chronic Illness and Late-Life Cognition: Evidence from Four Latin American Countries. *J Aging Health*. *J Aging Health*. 2018 Feb;30(2):262-304.
71. Alexander GC, Ballreich J, **Social MP**, Karmarkar T, Trujillo A, Greene J, Sharfstein J, Anderson G. Reducing branded prescription drug prices: A review of policy options. *Pharmacotherapy*. 2017 Aug 14.
72. Ballreich J, Alexander GC, **Social MP**, Karmarkar T, Anderson G. Branded prescription drug spending: a framework to evaluate policy options. *Journal of Pharmaceutical Policy and Practice*. 2017 Sept. Accepted for publication. DOI 10.1186/s40545-017-0115-9
73. Biehl J, **Social MP**, Amon JJ. On the Heterogeneity and Politics of the Judicialization of Health in Brazil. *Health Hum Rights*. 2016 Dec; 18(2):269-271.
74. Biehl J, **Social MP**, Amon JJ. The Judicialization of Health and the Quest for State Accountability: Evidence from 1,262 Lawsuits for Access to Medicines in Southern Brazil. *Health Hum Rights*. 2016 Jun;18(1):209-220.
75. Biehl J, **Social MP**, Amon JJ. The Challenging Nature of Gathering Evidence and Analyzing the Judicialization of Health in Brazil. *Cad Saude Publica*. 2016 Jun 1;32(6).
76. Fernandes GC, **Social MP**, Schuh AF, Rieder CR. Clinical and Epidemiological Factors Associated with Mortality in Parkinson's Disease in a Brazilian Cohort. *Parkinsons Dis*. 2015; 2015: 959304.
77. Quadri M, Fang M, Picillo M, Olgiati S, Breedveld GJ, Graafland J, Wu B, Xu F, Erro R, Amboni M, Pappatà S, Quarantelli M, Annesi G, Quattrone A, Chien HF, Barbosa ER; **International Parkinsonism Genetics Network**, Oostra BA, Barone P, Wang J, Bonifati V. Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. *Hum Mutat*. 2013 Sep;34(9):1208-15. [**Social MP** is listed among the network member authors in the Appendix of this publication].
78. Biehl J, Amon JJ, **Social MP**, Petryna A. Between the court and the clinic: lawsuits for medicines and the right to health in Brazil. *Health Hum Rights*. 2012 Jun 15;14(1):E36-52.
79. Siebert M, Donis KC, **Social M**, Rieder CR, Emmel VE, Vairo F, Michelin-Tirelli K, França M Jr, D'Abreu AC, Bettencourt C, Lima M, Lopes Cendes I, Saraiva-Pereira ML, Jardim LB.

Glucocerebrosidase gene variants in parkinsonian patients with Machado Joseph/ spinocerebellar ataxia 3. *Parkinsonism Relat Disord*. 2012 Feb;18(2):185-90.

80. **Socal, MP**. Between Policy and Justice: The Brazilian National Policy on Pharmaceuticals. *Journal of Public and International Affairs*, Fall 2010: 150-158.
81. **Socal MP**, Emmel VE, Rieder CR, Hilbig A, Saraiva-Pereira ML, Jardim LB. Intrafamilial Variability of Parkinson Phenotype in SCAs: Novel Cases Due to SCA2 and SCA3 Expansions. *Parkinsonism and Related Disorders*. 2009; 15: 374–378.
82. **Socal MP**, Bock H, Michelin-Tirelli K, Hilbig A, Saraiva-Pereira ML, Rieder CR, Jardim LB. Parkinson's Disease and the Heterozygous State for Glucocerebrosidase Mutations Among Brazilians. *Parkinsonism and Related Disorders*. 2009; 15: 76e78
83. Di Fonzo A, Chien HF, **Socal M**, Giraudo S, Tassorelli C, Iliceto G, Fabbrini G, Marconi R, Fincati E, Abbruzzese G, Marini P, Squitieri F, Horstink MW, Montagna P, Libera AD, Stocchi F, Goldwurm S, Ferreira JJ, Meco G, Martignoni E, Lopiano L, Jardim LB, Oostra BA, Barbosa ER; Italian Parkinson Genetics Network, Bonifati V. ATP13A2 Missense Mutations in Juvenile Parkinsonism and Young Onset Parkinson Disease. *Neurology*. 2007 May 8;68(19):1557-62.
84. Rieder CR, Schestatsky P, **Socal MP**, Monte TL, Fricke D, Costa J, Picon PD. A Double-Blind, Randomized, Crossover Study of Prosigne Versus Botox in Patients With Blepharospasm and Hemifacial Spasm. *Clinical Neuropharmacology*. 2007 Jan-Feb;30(1):39-42.
85. Trott A, Jardim LB, Ludwig HT, Saute JA, Artigalás O, Kieling C, Wanderley HY, Rieder CR, Monte TL, **Socal M**, Alonso I, Ferro A, Carvalho T, do Céu Moreira M, Mendonça P, Ferreirinha F, Silveira I, Sequeiros J, Giugliani R, Saraiva-Pereira ML. Spinocerebellar Ataxias in 114 Brazilian Families: Clinical and Molecular Findings. *Clinical Genetics*. 2006 Aug; 70(2): 173-6.
86. Kowacs F, **Socal MP**, Ziomkowski SC, Borges-Neto VF, Toniolo DP, Francesconi CR, Chaves ML. Symptoms of Depression and Anxiety, and Screening for Mental Disorders in Migrainous Patients. *Cephalalgia*. 2003 Mar;23(2):79-89.
87. Cunha GB, Rotta NT, Silva AR, Dieder AL, Wolf AL, Moser C, Silva FF, **Socal MP**, Silva PF, Margis R. Prevalence of prenatal exposure to cocaine in a sample of newborns from a university teaching hospital. *J Pediatr (Rio J)*. 2001 Sep-Oct;77(5):369-73. [article in Portuguese].
88. Kowacs F, **Socal MP**, Toniolo DP, Ziomkowski SC, Francesconi CRM, Chaves MLF. Migraine and Psychiatry Disorders. *Revista de Psiquiatria do Rio Grande do Sul*, 2001; 23(1): 19-36. [article in Portuguese].

*Articles, Editorials and other publications not peer-reviewed*

1. **Socal MP**. How the drug price negotiation program could affect Medicare Part D beneficiaries. *Stat News First Opinion (op-ed)*. September 08, 2023. <https://www.statnews.com/2023/09/08/medicare-part-d-drug-price-negotiations/>
2. **Socal MP**, Ballreich J, Crane MA, Anderson GF. The New Medicare Part D Out-Of-Pocket Cap Will Have Unintended Consequences. Here's How To Address Them. *Health Affairs Forefront*, October 06 2022. <https://www.healthaffairs.org/content/forefront/new-medicare-part-d-out-of->

pocket-cap-have-unintended-consequences-here-s-address-them

3. Cho J, Crane BS, Greene J, Long J, Muwanga J, Scharfstein J, **Socal MP**, Strodel R. The Pandemic and the Supply Chain: Addressing Gaps in Pharmaceutical Production and Distribution. (White paper; authors in alphabetical order). November, 2020.
4. Anderson GF, Cordeiro T, **Socal MP**, Vela L. Removing Waste from Drug Formularies: A practical guide to help employers remove waste from drug formularies and achieve savings for companies and employees while maintaining member satisfaction. (Guidebook; authors in alphabetical order). October 2019. <https://www.pbgh.org/initiative/waste-free-formularies/>
5. **Collaborator** in the Report: “Essential Medicines Supply Chain and Manufacturing Resilience Assessment” by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR)’s Next Foundry for American Biotechnology (NextFAB) program from the Advanced Regenerative Manufacturing Institute (ARMI). May 2022. Available from: <https://www.armiusa.org/biofabusa/roadmap-reports/>
6. **Socal MP**. *A Peça-Chave* [The Key Piece]. Article in Portuguese. Revista Piauí (Brazil). Ed. 164. May 2020. <https://piaui.folha.uol.com.br/materia/a-peca-chave/>
7. Bai G, **Socal MP**, Anderson GF. Policy Options To Help Self-Insured Employers Improve PBM Contracting Efficiency. Health Affairs Blog, May 29, 2019. <https://www.healthaffairs.org/doi/10.1377/hblog20190529.43197/full/>
8. Bai G, **Socal MP**, Sharp M, Pachman ES. Medicaid Managed Care Programs’ Contracts For Generic Drugs Are Inefficient. Health Affairs Blog, May 01, 2019. <https://www.healthaffairs.org/doi/10.1377/hblog20190426.775617/full/>

#### *Book Chapters*

1. **Socal MP**, Rieder CRM, Monte TL, Krug BC, Amaral KM. Distonias focais e Espasmo Hemifacial (Focal Dystonia and Hemifacial Spasm) In: Protocolos Clínicos e Diretrizes Terapêuticas (Clinical Protocols and Therapeutic Guidelines), 2nd Ed. Paulo Dornelles Picon & Alberto Beltrame, Eds. Brasília, DF, Brazil: Ministério da Saúde, 2010.
2. Finkelsztejn A, Stefani MA, Cristovam RA, Moraes GS, Teixeira LB, Schneider SB, **Socal MP**, Finkelsztejn KRP, Nogueira L. Escalas em Neurologia (Scales in Neurology). In: Rotinas em Neurologia e Neurocirurgia (Routines in Neurology and Neurosurgery). Márcia Lorena Fagundes Chaves, Alessandro Finkelstejn & Marco Antônio Stefani, Eds. Porto Alegre, RS, Brazil: Artmed Editora, 2008.

#### *Practice-Related Reports*

1. **Socal MP**. Policy memo. “Re: House Bill 1365 – “An Act Relative to Substitution of Biological Products by Pharmacies.” to The General Court Of New Hampshire; New Hampshire House Committee on Commerce and Consumer Affairs; and New Hampshire Prescription Drug Affordability Board. March 22, 2024.

2. **Socal MP**, Xuan AL, Anderson KE, Anderson GF. Manufacturing Insulins as Part of CalRx Generic Drug Label: How Much Can California Patients and Payors Save? Memo to the California Health and Human Services Agency. March 2022  
*Estimated savings to California patients and payors under CalRx biosimilar insulin prices.*
3. **Socal MP**, Long J, Crane MA, Anderson GF. Analysis for a State Generic Drug Label for the California Health and Human Services Agency. Memo to the California Health and Human Services Agency. January 2021.  
*Developed prioritization criteria for drugs to be manufactured as part of California's Generic Drug Label Initiative*
4. **Socal M**, Patel P, Ballreich J, Anderson G. Monitoring price hikes and utilization of off-patent drugs. Memo to Joshua Auerbach, Assistant MD Attorney General. September, 2017.  
*Outlined criteria for prioritizing drugs to be targeted by the Maryland's generic drugs price gouging law later overturned in court.*
5. Constenla D, Mirelman A, Alvaro A, Chen A, **Socal M**. The economic value of vaccines and immunization programs in low- and middle-income countries: An annotated bibliography. International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. Baltimore, MD: August, 2012
6. Gregory A, Kawamoto R, Lopez J, Palmer D, Petkun A, **Socal M**, Wong An, Woods G, Yin J. Implications for the Utilization of Advanced Medical Imaging: Comparative Effectiveness Research in the United States. Woodrow Wilson School, Princeton University: January 2010.

## **PRACTICE ACTIVITIES**

### **Research Findings Translation to Inform Policy and Practice**

#### ***Testimony – Federal Level***

**United States Congress - House Committee on Education and Labor**, May 05, 2021

Provided witness testimony at Congressional public hearing: “Lower Drug Costs Now: Expanding Access To Affordable Health Care”

**United States Congress - House Committee on Education and Labor**, September 26, 2019

Provided witness testimony at Congressional public hearing: “Making Health Care More Affordable: Lowering Drug Prices and Increasing Transparency”

**U.S. Food and Drug Administration**, May 13, 2019

Testified at Public Hearing: ‘The Future of Insulin Biosimilars’.

Presentation title: "Evaluating the interchangeability of insulin products – Which standards do we want?"

**U.S. Food and Drug Administration**, September 4, 2018

Testified at Public Hearing: ‘Facilitating Competition & Innovation in the Biological Products Marketplace.’

Presentation Title: "Improving Information Availability and Accessibility in the FDA Purple Book"



*Testimony – State Level*

**Alaska Senate Labor and Commerce Committee, March 20, 2024**

Testified at the public hearing on S.B. 121, "An Act relating to the Board of Pharmacy; relating to insurance; relating to pharmacies; relating to pharmacists; relating to pharmacy benefits managers; relating to patient choice of pharmacy; and providing for an effective date." Livestream recording at <https://www.akleg.gov/basis/Meeting/Detail/?Meeting=SL%26C%202024-03-20%2013:30:00&Bill=SB%20121>

**Vermont General Assembly, Senate Committee on Health and Welfare, January 26, 2024**

Testified at the public hearing on S.98, "An act relating to Green Mountain Care Board authority over prescription drug costs."

**Washington State Senate, Pre-Legislative Session Hearing on Drug Prices, December 01, 2022**

Testified at the public hearing with the committee Chair, Senator Cleveland, and the agency in charge of the state's drug pricing efforts, the Health Care Authority, on the provisions of the Inflation Reduction Act related to drug pricing.

**Maryland General Assembly Health and Government Operations Committee, March 15, 2022**

Testified at the public hearing on HB 1397: Insulin Cost Reduction Act. (An Act to cap insulin out-of-pocket payments for privately insured and Medicare beneficiaries in the state of Maryland). Bill signed into law by Maryland Governor Larry Hogan on May 19, 2022.

**Maine Prescription Drug Affordability Board, October 26, 2021**

Testified on wasteful drug spending and ways to remove such spending from drug formularies.

*Presentations to policy makers and other stakeholders*

2024

**Center for Strategic and International Studies (CSIS) – November 19, 2024**

Event: "Strengthening North American Pharmaceutical Supply Chains."

Audience:

Location: Web-based event

**Office of the Assistant Secretary for Policy and Evaluation (ASPE) – November 01, 2024**

Event: Web-based presentation of the Johns Hopkins Drug Supply Chain Dashboard

Audience: 2 senior staff members

**Alliance for Patient Access (AfPA) – September 24, 2024**

Event: AfPA National Policy & Advocacy Summit

Presentation: "Pressure on Patients" expert panel

Audience: 100 in-person attendees (mainly patients and advocates)

Location: Washington, DC.

**Congressman Jake Auchincloss (D, MA-04) – Sept 18, 2024**

Event: web-based discussion on PBM reform bills.

Audience: Rep. Auchincloss, Jess Wysocki (staff), Prof. Craig Garthwaite (Northwestern U).

**David B. Zlotnick, Deputy Attorney General, California Dep. of Justice- March 20, 2024;  
September 17, 2024**

Event: Web-based presentation on insulin pricing dynamics in the US market 2001-2024.

Audience: 1 person (Mr. Zlotnick)

Location: Web-based

**The Hill (media outlet) - March 06, 2024**

Event: in-person and simulcast panel discussion for congressional staff and advocates

Audience: 100 in-person (plus livestream) congressional staffers and advocates

Presentation: Prescribing PBM reform, accelerating transparency with bipartisan action.

Location: Washington, DC.

**International Negotiation Competition – Brazilian Chapter – March 08, 2024**

Event: web-based panel

Audience: 80 faculty and students from top Brazilian universities

Presentation: Using negotiation skills in public health policymaking (keynote speaker)

Location: online event

**Hopkins Geriatric Medicine and Gerontology Grand Rounds – February 22, 2024.**

Event: Monthly meeting of the Department of Geriatric Medicine and Gerontology, Johns Hopkins Hospital

Audience: practicing physicians, residents, researchers, and trainees

Presentation: Mail Order versus Retail Pharmacy Use among Medicare Part D Beneficiaries with Alzheimer’s Disease and Related Dementias (ADRD) (presented by Jeromie Ballreich)

Location: online presentation for in-person audience in Baltimore, MD.

**National Association of Medicaid Directors (NAMD) – February 12, 2024**

Event: Web-based, biweekly call for state Medicaid CFOs.

Audience: 80 state Medicaid directors, pharmacy benefit directors, and CFOs.

Presentation: “Medicaid Rebate Cap Removal: Main Implications and Unintended Consequences”

**National Coalition for Cancer Survivorship (NCCS) – January 17, 2024.**

Event: NCCS Cancer Policy Roundtable Highlights Informational Webinar

Audience: 115 nationwide cancer policy advocates

Location: online event

2023

**Center for Medicare and Medicaid Innovation (CMMI) – September 13, 2023**

Event: Meeting on gene therapies for sickle cell disease

Audience: 6 CMMI

Location: Baltimore, MD

**National Conference for State Legislatures (NSCL) – June 21, 2023**

Event: Prescription Drug Peer Learning Group for State Legislators.

Panels: “Insulin Affordability: What’s next?” and “Pharmacy Benefit Managers: Caught in the Middle.”

Location: Portland, Oregon

**Maryland State of Reform Health Policy Conference – June 14, 2023**

Panel: “Methods to Lower the Cost of Drugs”

Audience: 30 decision-makers representing Maryland health insurers, hospitals, pharmacies, drug manufacturers, advocates, and state administrators, legislators, and their staff.

Location: Baltimore, MD

**T1 International** (Association representing persons with type 1 diabetes) – June 28, 2023

Event: Monthly meeting of the T1 International Federal Working Group

Presentation: policies to solve drug shortages and increase access to insulin

Audience: 10 members of T1 International

Location: online event

**Health Canada, Office of Pharmaceuticals Management Strategies (Strategic Policy Branch)- June 20, 2023.**

Event: Expert Speaker Series. Lecture: Pharmaceutical Supply Chains.

Audience: 20 staff members from various offices of the Health Canada agency

Location: Online event

**Public Citizen & Families USA: Rx Allies Working group – June 15, 2023**

Event: Monthly meeting

Presentation: Drug shortages and potential solutions

Audience: 80 participants including activists and experts across the U.S. (progressive & grassroots groups, labor unions, think tanks & academics)

Location: online event

**Brazilian National Association of Private Hospitals (Associação Nacional de Hospitais Privados – ANAHP) - April 03, 2023.**

Event: seminar on Introduction to the US health care system.

Audience: 30 Brazilian Senators and Federal Deputies.

Location: Baltimore, MD.

2022

**National Association of Medicaid Directors (NAMD) – November 15, 2022**

Event: NAMD Fall Conference.

Panel: “Pharmaceutical Policy”

Audience: 120 conference participants

Location: Washington, DC

**National Academies of Science, Engineering and Medicine (NASEM)** -October 24 and 25, 2022  
Event: Stakeholder Meeting "Building Resilience into the Nation's Medical Product Supply Chains"  
Audience: 30 NASEM experts representing academia, industry, government, and patient groups  
Location: web-based event

**National Conference for State Legislatures (NCSL)** - October 12, 2022  
Event: Health Legislative Staff Seminar: Achieving Affordable Quality Health Care Systems  
Panel: "State Approaches to Prescription Drug Affordability"  
Audience: 40 state legislative staff members  
Location: Atlanta, Georgia

**National Conference for State Legislatures (NCSL)** – June 06, 2022  
Event: State Policy Seminar: Levers to Address Health Costs  
Panel: "Prescription Drugs and Creating Competition"  
Audience: 30 state legislators  
Location: Denver, Colorado

**Maryland State of Reform Health Policy Conference.** – May 04, 2022  
Event:  
Panel: "Pharmacy: Balancing Access and Costs"  
Audience: 15 participants representing Maryland health insurers, hospitals, pharmacies, drug manufacturers, advocates, state administrators and legislators  
Location: Baltimore, MD

**White House Domestic Policy Council – October - December 2022**  
Event: briefings on (1) implementation of the drug pricing provisions in the Inflation Reduction Act; (2) potential impact of drug shortages on the penalty provisions of the IRA inflation rebate; and (3) recent shortages of pediatric preparations fever and anti-inflammatory medications.  
Audience: 8 Domestic Policy Council members  
Location: web based

**CMMI and CMS – October and November 2022**  
Event: briefings on (1) implementing the drug pricing provisions in the Inflation Reduction Act, and (2) steps the Administration can take to reduce drug spending without legislative action.  
Audience: 12 CMS and CMMI leadership and staff members  
Location: web based

**ASPE – October and November 2022**  
Event: briefings on: (1) steps to implement the drug pricing provisions in the Inflation Reduction Act, and (2) drug shortages - causes and potential solutions.  
Audience: 10 ASPE leadership and staff members  
Location: web based

**United States Congress – September to December 2022**  
Event: web-based briefings to Congressional committees. Topics: (1) steps to implement the drug pricing provisions in the Inflation Reduction Act, (2) US pharmaceutical supply chain and the

potential impact of drug shortages on the inflation rebate penalty established by the Act.  
Audience: staff members of Senate Finance Committee, Senate HELP Committee, House Committee on Oversight and Reform, House Committee on Energy and Commerce, House Ways and Means Committee.  
Location: web based

**Center for Medicare and Medicaid Innovation (CMMI) – August 23, 2022**

Event: internal meeting; topic: CMMI Demonstration Opportunities post-Inflation Reduction Act  
Audience: 2 CMMI staff members  
Location: web-based

**Food and Drug Administration – August 03, 2022**

Event: Brown bag health economics seminar ("Manufacturer-sponsored coupons support insulin product line extensions")  
Audience: 20 FDA staff members  
Location: Web-based.

**Agency for Health Care Research and Quality (AHRQ) – July 07, 2022**

Event: internal meeting ("Insulin: competition and affordability in the US market")  
Audience: 2 AHRQ staff working on a report on insulin affordability for Congress  
Location: Web-based

**Endpoint News - June 21, 2022**

Event: Panel: "Revamping the FDA's prized accelerated approvals"  
Audience: 180 members of the public  
Location: web-based

**National Conference for State Legislatures – June 06, 2022**

Event: Seminar: Levers to Address Health Costs (Panel: "Prescription Drugs and Creating Competition")  
Audience: 80 State senators, delegates and representatives  
Location: Denver, Colorado

**Maryland State of Reform Health Policy Conference. – May 04, 2022**

Event: Health Policy Conference (Panel: "Pharmacy: Balancing Access and Costs")  
Audience: 20 Maryland elected officials and public health decision-makers  
Location: Baltimore, MD

**National Association of Medicaid Directors (NAMD) – CFO Affinity group – March 21, 2022**

Event: Web-based, biweekly call for state Medicaid CFOs.  
Audience: 80 state Medicaid directors and CFOs.  
Presentation: "The Drug Development Pipeline: An Outlook for State Medicaid Directors"

**U.S. Senator Ben Cardin - March 18, 2022**

Event: Virtual conversation (Panel: "High Price of Prescription Drugs: Taking Action to Lower Costs")  
Audience: 100 Hill staffers, decision-makers, and general public

Location: online through Facebook Live

2021

**Congressional Hispanic Caucus Institute – November 15, 2021**

Event: web-based panel presentation

Audience: 100 members of Congress, staff members, and the general public

Presentation title: “Congressional Hispanic Caucus Institute Fall Summit – Panel: The Future of Accessible Medicine”

**Maine Prescription Drug Affordability Board – October 25, 2021**

Event: web-based presentation

Audience: 20 participants; members of the Prescription Drug Affordability Board of the state of Maine, the National Academy of State Health Policy (NASHP), and members of the public.

Presentation title: “Using Waste-free Formularies to Lower Prescription Drug Costs”

**Doctors For America – September 28, 2021**

Event: Webinar

Audience: about 50 physicians and medical students located nationwide

Presentation title: Lunch & Learn – Myths & Facts of Drug Pricing Proposals

**University of Pennsylvania Leonard Davis Institute of Health Economics- September 17, 2021**

Event: Webinar

Audience: 100+ health economists, physicians, and other scholars

Presentation title: “Drug Pricing: Policy and Politics”

2020

**United States Congress - 2020**

Event: web-based presentations to Congressional committees

Audience: staff members of Senate Finance Committee, Senate HELP Committee, House Committee on Oversight and Reform, House Committee on Energy and Commerce, House Ways and Means Committee.

Presentations topics: US pharmaceutical supply chain, drug shortages associated with COVID-19 epidemic, advanced purchasing commitments to support federal government drug price negotiations, biosimilar utilization in Medicare Part B, and Orphan Drug Act reform.

**Medicare Payment Advisory Commission (MEDPAC) – November 19, 2020**

Event: web-based presentation

Audience: about 5 MEDPAC staff members

Presentation topics: advanced purchasing commitments to support federal government drug price negotiations, biosimilar utilization in Medicare Part B, and Orphan Drug Act reform.

**Congressional Budget Office (CBO) – November 12, 2020**

Event: web-based presentation

Audience: about 10 CBO staff members

Presentation topics: advanced purchasing commitments to support federal government drug price negotiations, biosimilar utilization in Medicare Part B, and Orphan Drug Act reform.

**Self-Insurance Institute of America, Inc. (SIIA) - October 15, 2020**

Event: SIIA's 40<sup>th</sup> Virtual Annual National Conference & Expo

Audience: self-insured employers and their representatives (pharmacy benefit managers, health care consultants, insurance brokers, and others).

Presentation title: Removing Waste From Drug Formularies in Self-Insured Health Plans

**Centers for Medicare and Medicaid Services (CMS) – September 03, 2020**

Event: web-based presentation

Audience: about 10 CMS staff members

Presentation topics: biosimilar utilization in Medicare Part B, branded drug formulary placement in Medicare Part D, and Orphan Drug Act reform.

**Health Rosetta - August 25, 2020**

Event: Webinar

Audience: over 180 health benefit consultants, insurance brokers, third-party administrators and benefit managers working with self-insured employers

Presentation title: The Waste-Free-Formulary

**Maine's State Employee Health Commission (SEHC) – June 18, 2020**

Event: Web-based meeting

Audience: 24 members of the executive manager and labor advisory group of the Maine's State Employee Health Commission, which reviews and approves health plan design changes

Presentation title: Implementing a Waste-Free-Formulary

**National Academy for State Health Policy (NASHP) – June 5, 2020**

Event: Webinar

Audience: over 60 state public health officials, benefit managers, and state employee health programs staff members nationwide

Presentation title: Removing Wasteful Drug Spending from State Health Benefit Programs

**Johns Hopkins Drug Access and Affordability Initiative - January 30, 2020**

Event: Webinar

Audience: 15 senior health officials from New Jersey, New York, California and Maryland.

Presentation title: Removing Wasteful Drug Spending from State Health Benefit Programs

**Johns Hopkins Science Policy Group, Johns Hopkins University - August 12, 2020**

Event: virtual town hall on prescription drug affordability

Audience: about 50 graduate and undergraduate students

Presentation title: Landscape of federal level and what the outcomes of the presidential election could mean for the next cycle of drug pricing policies

2019

**United States Congress - 2019**

Event: Presentations to Congressional committees

Audience: staff members of Senate Aging Committee, Senate Finance Committee, Senate HELP Committee; staff members in the office of Rep. Nancy Pelosi, office of Rep. Diana DeGuetta, and office of Rep. Lloyd Doggett.

Presentation topics: Insulin coverage and placement in Medicare part D formularies, Drug Formularies in Medicare Part D Prescription Drug Plans, Biosimilars and Orphan Drugs to staff directors.

**Association of Health Care Journalists, November 14, 2019**

Event: Webinar

Audience: about 50 health care journalists

Presentation title: Lowering Drug Prices: What Can Large Corporations Do?

**Association of Health Care Journalists, November 04, 2019**

Event: Lecture

Audience: about 25 recipients of the 2019 National Cancer Reporting fellowship program at the National Cancer Institute, National Institutes of Health

Presentation title: Tackling the Cost of Drugs and Treatment

**Latino Public Health Network, Johns Hopkins Bloomberg School of Public Health, December 03, 2019**

Event: Career panel

Audience: about 50 public health graduate students

Presentation topic: Latinas in Public Health Career Panel

2018

**United States Congress - 2018**

Event: presentations to Congressional Committees

Audience: staff directors and members of Ways & Means Committee, Energy & Commerce Committee, House Committee on Oversight and Reform.

Presentation topics: drug formularies in Medicare Part D prescription drug plans, biosimilars and orphan drugs

2017

**MedChi, The Maryland State Medical Society, September 13, 2017**

Event: invited lecture - debate

Audience: about 50 MedChi members

Presentation title: Pharma Transparency: Good or Bad? (defended the "pro" side)

***Consultations with policy makers and other stakeholders***

2024-2024

2020-ongoing



**CalRx California Generic Drugs Label Initiative – February 2020-current**

Providing technical assistance on prioritization criteria for drugs to be targeted by the Initiative, potential savings to payors and patients, and distribution channel needs of targeted drugs.

2023-2023

**Centers for Medicare and Medicaid Services (CMS)**

Provided technical expertise and advise to staff members on issues of gene therapy payment models and drug shortage solutions.

2021-2023

**White House Domestic Policy Council, 2021-2023**

Provided technical expertise and advice to staff members on drug pricing issues, supporting the drafting and posteriorly the enactment of the Inflation Reduction Act of 2022, and on supply chain

2020-2021

**House of Representatives Committee on Oversight and Reform – October 2020-March 2021**

Reviewer of confidential reports investigating drug pricing practices by pharmaceutical manufacturers such as Celgene, Mallinckrodt, Abbvie, and others.

2018-2019

**Maryland Citizen’s Health Initiative – Maryland Health Care for All Coalition**

Collaborated with consumer coalition led by Vinny DeMarco on text and data for a bill introducing a prescription drug affordability board in Maryland.

***Other practice activities***

2024

**Organizer and Moderator, Panel: Leveraging the University Teaching Mission to Advance Policy-Making.**

Event: Johns Hopkins University Provost DELTA Teaching Symposium (concurrent session)

Panelists: Melisa Lindamood (Hopkins Federal Affairs), Robert Kearns (JHU SOM), Keshia Pollack Porter (JHSPH), and Joshua Sharfstein (JHSPH)

Audience: 40 participants

Location: Johns Hopkins University Homewood Campus, Baltimore, MD, with online option

2023

**Co-Organizer, Hopkins 2023 Innovations in the Biopharmaceutical Industry Conference**

Event: Bringing together industry, academia, and regulators, discussed innovations in biopharma; role of recent legislation and regulatory changes; impact on patients and payors; outlook into future

Audience: 75 participants,

Location: Carey Business School Harbor East Campus, Baltimore, MD

**Research finding dissemination through media appearances and other communication venues**

2024

- Interview with Alex Knapp (Forbes) on China tariffs on drugs – November 08, 2024

- Interview with Zoey Becker (Fierce Pharma) on election policy implications – October 29, 2024
- Interview with Lisa Jarvis (Bloomberg Newsroom) on shortage solutions - October 23, 2024
- Interview with Lizzy Lawrence from Stat on shortages and compounding - October 22, 2024
- Interview with Daniel Gilbert from Washington Post on Mounjaro shortages - October 18, 2024
- Interview with Danielle Brown (Maryland Matters) on IV fluid shortages – October 10, 2024
- Interview with Kate Knibbs (Wired) on GoodRx pricing model – October 01, 2024
- Interview with Kristian Villesen (Dagbladet Information, Danmark) on NovoNordisk pricing policies for Wegovy and Ozempic in the USA and internationally – October 01, 2024
- Interview with Tim Casey from AIS Health on Gene Therapies – Sept 19, 2024
- Interview with Anikka Constantino from CNBC on Harris/Trump outlook – Sept 17, 2024
- Interview with Tim Casey from AIS Health on Part D Premium Demonstration – Sept 10, 2024
- Interview with Ike Swetlitz from Bloomberg News on Prior Authorization – Sept 5, 2024
- Interview with Caleb McCollough from PolitiFact on impact of the IRA- August 22, 2024
- Interview with Deena Beasley from Reuters on Medicare’s negotiated prices – Aug 21, 2024
- Interview with Sharmila Devi from Lancet Oncology on drug shortages – Aug 19, 2024
- Interview with Ian Lopez from Bloomberg Law on Medicare drug prices – Aug 15, 2024
- Interview with Korin Miller from Fortune Magazine on the Harris campaign – August 06, 2024
- Interview with Scaachi Koul from Best Case/Audible podcast on GLP-1 drugs – Aug 01, 2024
- Interview with Jared Facundo from Capitol Forum on Medicare specialty tier – July 26, 2024
- Interview with Nyah Phengsitthy from Bloomberg Law on Medicare prices – July 26, 2024
- Interview with Maia Anderson from Morning Brew on Kisunla drug prices – July 16, 2024
- Interview with Shawn Radcliffe from Healthline on GLP-1 drug competition – April 02, 2024
- Live TV and radio interview with Bloomberg Businessweek on drug importation- Feb 22, 2024
- Interview with Arielle Hixson from Cox Media Group on high drug prices – January 24, 2024
- Johns Hopkins Bloomberg School of Public Health Live Press Briefing – January 24, 2024
- Interview with Bailey Schulz from USA Today on Medicare price negotiations – Jan 18, 2024

## 2023

- Interview with NPR Marketplace on Medicare drug negotiations – December 29, 2023
- Interview with Charlotte Huff from ACP Internist on insulin pricing – December 04, 2023
- Interview with Alice Tracey from The Capitol Forum on brown, white and clear bagging – November 14, 2023.
- Interview with Rachel Nania from AARP Health and Medicine on paxlovid – October 30, 2023
- Interview with Adam Bluestein from Fast Company on insulin pricing – October 30, 2023
- Interview with Lexi Lonas from The Hill on ADHD drug shortages – October 23, 2023
- Interview with Aaron Gregg from the Washington Post on pharmacy closures. October 19, 2023
- Interview with Christiaan Hetzner from Fortune Magazine on drug shortages- October 13, 2023
- Live interview on Inflation Reduction Act -CSPAN The Washington Journal – September 2023
- Live interview on Inflation Reduction Act -NPR morning edition - September 2023
- Live interview with Ayesha Rascoe on shortage of ADHD medications – NPR weekend edition Sunday – September 08 2023
- Interview by Aimee Picchi for CBS News Moneywatch on Medicare drug price negotiation – September 2023
- Interviewed for a televised segment by Pedro Paiva, Brasil de Fato, on drug shortages – August

## 2023

- Interviewed for JHSPH’s Public Health on Call Podcast by Prof. Josh Sharfstein on shortages of lifesaving chemotherapy drugs – July 07, 2023 <https://johnshopkinssph.libsyn.com/633-the-far-reaching-impacts-of-drug-shortages-affecting-cancer-treatments>
- Interviewed by Prof. Lainie Rutkow for Johns Hopkins University’s Live briefing on prescription drug shortages – June 02, 2023 <https://publichealth.jhu.edu/events/2023/johns-hopkins-briefing-prescription-drug-shortages>
- Interviewed for a televised segment by Adriana Loeff, Univision, on shortage of pediatric medications. April 04, 2023.
- Interviewed by Ian Philbrick, The New York Times, on the impact and potential savings from the Inflation Reduction Act. March 27, 2023.
- Interviewed by Alice Tracey and Lauren Wadsten, The Capitol Forum, on PBM coverage of anti-MS drug Tecfidera. March 27, 2023.
- Interviewed by Benjamin Ryan, The New York Times, on the impact of reductions in insulin list prices and the introduction of CalRx biosimilar insulin. March 20, 2023.
- Interviewed by Grace H Fernandez, Communications and Marketing Specialist, Johns Hopkins Bloomberg School of Public Health on the impacts of insulin price reductions. March 02, 2023
- Interviewed for a recorded podcast, "Health Affairs: Drug Podissey", on competition and vulnerabilities in the US pharmaceutical supply chain. February 28, 2023.
- Interviewed by Jessica Grose, The New York Times, on shortages of pediatric medications. January 10, 2023.

## 2022

- Interviewed for a recorded podcast, "Tradeoffs", on the anticipated impact of market entry of Humira biosimilars. December 07 2022
- Interview by Daniel Gilbert, Washington Post, on drug shortages, November 30, 2022
- Panelist on Endpoint News panel “Revamping the FDA's prized accelerated approvals” June 21, 2022 (web-based event)
- Panelist on US Senator Ben Cardin’s Facebook Live event “High Price of Prescription Drugs: Taking Action to Lower Costs” March 18, 2022
- Interviewed by Matt Levin, Reporter, Marketplace/NPR, on Medicare drug pricing negotiations, August 08 2022
- Interviewed by Lily Jamali, Reporter, Marketplace/NPR, on Post Roe vs. Wade pharmacy limitations to emergency contraception, June 28, 2022
- Interviewed by Andrea Perdomo, reporter with the Tradeoffs podcast, on contrast media shortage and the vulnerability of our medical supply chain, June 02, 2022
- Interviewed by Mary Ellen Schneider, Health/Medical Writer & Editor of ASH Clinical News, a publication of the American Society of Hematology, on global cost of hematology drugs. May 04, 2022
- Interview with Shawn Radcliffe, writer at Healthline.com, on the U.S. House Oversight Committee Report on high prices for insulin and other prescription drugs. January 06, 2022.

## 2021

- Interviewed by Laura Griffin, reporter with LastWeekTonight TV show, on insulin prices, access, and affordability. December 02, 2021

- Interview with Yasmin Tayag, reporter with The Capsule, Fortune Magazine's weekly newsletter, on President Biden's prescription drug pricing plan. November 03, 2021
- Interviewed by Nancy Marshall-Genzer, Senior Reporter, Marketplace Washington Bureau, NPR, on efforts to onshore the US pharmaceutical supply chain. September 30, 2021.
- Interviewed by Celia Llopis-Jepsen, Health reporter, of NPR station KCUR 89.3FM, Kansas News Service, Kansas City, MO, on rebates and drug prices. May 07, 2021
- Interviewed by Eloá Orazem, reporter, Brasil de Fato, on COVID vaccine patents. May 24, 2021<sup>1</sup>
- Interviewed by Grace H Fernandez, Communications and Marketing Specialist, Johns Hopkins Bloomberg School of Public Health on the impacts of COVID-19 on diabetes and insulin. April 07, 2021<sup>2</sup>
- Interviewed by Jessie Jiang, reporter, Voice of America (VOA News) on the US pharmaceutical supply chain, April 27, 2021.
- Interviewed by Abraham Kim, Clinical Content Editor, Doximity, on the Trump's administration executive order on price transparency<sup>3</sup>. April 08, 2021.

## 2020

- Interviewed by Ryan Levi, Producer, Tradeoffs Podcast, on the California Generics Initiative.
- Interviewed by Stephen Morrissey, Executive Managing Director of the New England Journal of Medicine, on draft guidance from the FDA aimed at promoting competition in the insulin market. Supplement to the N Engl J Med 2020; 382:981-983.  
<https://www.nejm.org/action/showMediaPlayer?doi=10.1056%2FNEJMdo005708&aid=10.1056%2FNEJMp1916387&area=>
- Orphan Drug Study featured by the Center of Biosimilars – News (June 25, 2020). *Orphan Drug Exclusivity Keeps Biosimilars Off the Market, Study Says*.  
<https://www.centerforbiosimilars.com/news/orphan-drug-exclusivity-keeps-biosimilars-off-the-market-study-says>
- Report to ERIC: The ERISA Industry Committee featured in Stat News – Pharnalot. *Large employers could have saved money if more biosimilars had been prescribed* (April 02, 2020).  
<https://www.statnews.com/pharnalot/2020/04/02/biosimilars-biologics-drug-prices-remicade/>
- Report to ERIC: The ERISA Industry Committee featured by the Center of Biosimilars – News (April 01, 2020) *Study: Employers Can Save With Biosimilars*.  
<https://www.centerforbiosimilars.com/news/study-employers-can-save-with-biosimilars>
- Medicare Bundled Payments study featured in EurekAlert news from the American Association for the Advancement of Sciences. February 20, 2020. *Bundled payments have not led to 'cherry-picking' of patients for joint replacement surgery*.  
[https://www.eurekalert.org/pub\\_releases/2020-02/wkh-bph022020.php](https://www.eurekalert.org/pub_releases/2020-02/wkh-bph022020.php)

## 2019

- Quote from FDA Testimony featured in Politico. *Insulin meeting shines light on biosimilar barriers* <https://www.politico.com/newsletters/prescription-pulse/2019/05/14/insulin-meeting->

---

<sup>1</sup> <https://www.brasildefato.com.br/2021/05/26/eua-passam-a-apoiar-quebra-das-patentes-de-vacinas-e-isolam-ainda-mais-o-brasil>

<sup>2</sup> <https://www.jhsph.edu/covid-19/articles/the-impacts-of-covid-19-on-diabetes-and-insulin.html>

<sup>3</sup> See: Kim A. The New Price Transparency Rule Aims to Lower Drug Costs. But Will It Work? [https://opmed.doximity.com/articles/the-new-price-transparency-rule-aims-to-lower-drug-costs-but-will-it-work?\\_csrf\\_attempted=yes](https://opmed.doximity.com/articles/the-new-price-transparency-rule-aims-to-lower-drug-costs-but-will-it-work?_csrf_attempted=yes)

shines-light-on-biosimilar-barriers-436306

- Interviewed by Michelle Meyer from Managed Healthcare Executive Magazine on “*What Healthcare Execs Need to Know About Medicare Paying for CAR-T Cell Treatments*”
- Interviewed by Joseph Burns from Managed Care Magazine on the impact of rebates on large employer’s drug formularies.
- Interview with Mark Verdencia from United States Pharmacopeia on manufacturing standards for insulin.
- Interviewed by Dana G Smith from Medium media on high insulin prices.

2018

- Collaborated with Kaiser Health News’ reporter Jay Hancock to inform a news article on favorable placement of branded products in Medicare part D prescription drug formularies.
- Interviewed by Record TV News (Brazilian TV station) on the comparison between the US health care system and the Brazilian health care system.

## CURRICULUM VITAE

**Mariana P. Socal, M.D., M.Sc., M.P.P., Ph.D.**

### PART II

#### TEACHING & MENTORING

##### *Advisees*

##### Doctoral-level Advising (JHSPH)

Ilina Odouard (PhD): Primary advisor, 2024-present  
Jianing (Johnny) Li (DRPH): Primary advisor, 2024-present  
Alexander Bastian (DrPH): Primary advisor, 2024-present  
Alysia Drummond (DrPH): Co-advisor (with Alyssa Moran), 2022-present  
Elaine Boing (DrPH): Co-Advisor (with Gerard Anderson), 2020 – present  
Laura Tolosa (DrPH): Primary advisor, 2022–2023 (dropped out)

##### Doctoral-level Advising: Preliminary Oral Participation (JHSPH)

Jianing (Johnny) Li (DRPH): Concentration Oral Exam, 2024 (role: advisor)  
Amanda Teeple (DRPH), School-Wide Oral Exam, 2024 (role: committee chair)  
Ingrid Wong (DRPH, Tsinghua), Concentration Oral Exam, 2024 (role: alternate member)  
Amanda Teeple (DrPH), Concentration Oral Exam, 2024 (role: committee member)  
Alysia Drummond (DrPH), Concentration Oral Exam, 2024 (role: advisor, member)  
Abigail Neel (DrPH), Preliminary Exam, 2023 (role: alternate committee member)  
Zachary Enumah (PhD), Preliminary Exam, 2021 (role: committee member)  
Michael DiStefano (PhD), Preliminary Exam, 2018 (role: alternate committee member)  
Farah Yehia (PhD), Preliminary Exam, 2018 (role: committee member)

##### Doctoral-level Advising: Final Oral Participation (JHSPH)

Angela Liu (PhD), Final Oral Exam, 2024 (role: alternate committee member)  
So Yeon Kang (PhD), Final Oral Exam, 2023 (role: alternate committee member)  
Kiefer Ahn (PhD), Final Oral Exam, 2022 (role: alternate committee member)  
Zachary Enumah (PhD), Final Oral Exam, 2022 (role: committee member)  
Sonal Parasrampuriah (PhD), Final Oral Exam, 2019 (role: alternate committee member)

##### Johns Hopkins Center for Global Health Established Field Placement Advising

(Project: Human Nutrition in Brazil)  
JHSPH (2023): Yunxiang Sun  
JHSPH (2022): Minghui Zhang  
JHSPH (2021): Lauren Bisi

##### Masters' Capstone Advising

JHSPH (2024-25): Paola Sormani [MPH]  
JHSPH (2024-25): Deanna Portero [MPH]

JHSPH (2024-25): Tiago Araujo [MPH]  
JHSPH (2024-25): Cassandra Walker [MPH]  
JHSPH (2024-25): Michael Carter [MPH]  
JHSPH (2024-25): Bryce St.Clair [MPH]  
JHSPH (2023-24): Lisa Peters [MPH]  
JHSPH (2023-24): Sam Hannon [MPH]  
JHSPH (2023-24): Sophie Dilek [MPH]  
JHSPH (2023-24): Jen Black [MPH]  
JHSPH (2022-23): Darci Corwen-Garber [MPH]  
JHSPH (2022-23): Nirmal Choradia [MPH]  
JHSPH (2022-23): Audrey Cheng [MPH]  
JHSPH (2022-23): Abigail Pirron [MPH]  
JHSPH (2022-23): Mariam Assi [MPH]  
JHSPH (2022-23): Karime Kalil Machado [MPH]  
JHSPH (2021-22): Joseph Hydell [MPH]  
JHSPH (2021-22): Rachel Lamparelli [MPH] - **Won MPH Capstone Award 2022**  
JHSPH (2021-22): Laron Johnson [MPH]  
JHSPH (2021-22): Jennifer Hsu [MPH]  
JHSPH (2021-22): Amelia Murphy [MPH]  
JHSPH (2020-21): Fabrício Garcia [MPH]- **Won MPH Capstone Award 2022**  
JHSPH (2019-20): Jiahe Liang [MPH] - **Won MPH Capstone Award 2020**  
JHSPH (2018-19): Sarah Vick, MD [MPH] - **Won MPH Capstone Award 2019**  
JHSPH (2018-19): Daniel Gorbaty [MPH]  
JHSPH (2018-19): Yaacov Anziska, MD [MPH]

**Masters-level Academic Advising**

JHSPH (2023-2025): Academic Network Advisor (ANA) for 5 part-time MPH students  
JHSPH (2022-2024): Academic Network Advisor (ANA) for 15 part-time MPH students  
JHSPH (2022-2023): Academic Network Advisor (ANA) for 10 full-time MPH students  
JHSPH (2019-20): MonYi Lwin [MSPH in Health Policy and Management]  
JHSPH (2018-19): Dewyn Bell [MSPH in Health Policy and Management]  
JHSPH (2018-19): Diana Teremzawi [MSPH in Health Policy and Management]

**General Internal Medicine Residency Capstone Advising (Universidade Luterana do Brasil)**

2009: Fabíola Madalozzo da Costa, MD  
2009: Vanice Ferraza Zaltron, MD

**M.D. Thesis Advising (Universidade Luterana do Brasil, Brazil)**

2009: Fernando Muratore, MD  
2009: Eduardo Fialho Ruschel, MD  
2009: Aline Tagliari Kurtz, MD  
2008: Tiago Hermes Maeso Montes, MD  
2008: Fernando Godoy Neves, MD

2008: Marta Ryff Moreira, MD  
2008: Leticia Machado Rosa da Silva, MD  
2008: Ana Caroline Gazzolla, MD  
2007: Jean Franco Rostellato Marin, MD

M.D. Thesis Examination Committee (Universidade Luterana do Brasil, Brazil)

2007: Thais Pletsch Schaefer, MD (role: committee member)  
2007: Bethânia Camara Ehlers, MD (role: committee member)  
2007: Rodrigo Meirelles Borba, MD (role: committee member)

***Faculty Mentorship***

JHSPH (2022-current): Dr. Yang Wang, PhD. Assistant Scientist, HPM Department

***Classroom Instruction (Principal Instructor)***

**Instructor**, PH 308.630.51 U.S. Pharmaceutical Policy

Course newly created by Mariana Socal in Summer 2024 (Summer Institute)  
2024 Enrollment: 8  
Johns Hopkins Bloomberg School of Public Health (3 credits)  
Department of Health Policy and Management, Washington, DC

**Instructor**, PH 308.630.01 U.S. Pharmaceutical Policy.

Course newly created by Mariana Socal in Spring 2019 (4<sup>th</sup> term)  
2024 Enrollment: 65 **Received Outstanding Teaching Recognition from the JHSPH Dean**  
2023 Enrollment: 87 **Received Outstanding Teaching Recognition from the JHSPH Dean**  
2022 Enrollment: 80 **Received Outstanding Teaching Recognition from the JHSPH Dean**  
2021 Enrollment: 45 **Received Outstanding Teaching Recognition from the JHSPH Dean**  
2020 Enrollment: 34 **Received Outstanding Teaching Recognition from the JHSPH Dean**  
2019 Enrollment: 33 **Received Outstanding Teaching Recognition from the JHSPH Dean**  
Johns Hopkins Bloomberg School of Public Health (3 credits)  
Department of Health Policy and Management, Baltimore MD

**Co-Instructor**, PH 300.651.01 Introduction to the U.S. Health Care System (with Profs. Dan Polsky and Craig Pollack) (1<sup>st</sup> term). (2020-2022)

2022 Enrollment: 190 masters and doctoral students  
2021 Enrollment: 200 masters and doctoral students  
2020 Enrollment: 149 masters and doctoral students  
Johns Hopkins Bloomberg School of Public Health (3 credits)  
Department of Health Policy and Management, Baltimore MD

**Co-Instructor**, PH 309.670.01 Comparative Health Insurance (with Gerard Anderson and Amber Willink). (2<sup>nd</sup> term) (2018-2019)

2019 enrollment: 15 masters and doctoral students  
2018 enrollment: 40 masters and doctoral students



Johns Hopkins Bloomberg School of Public Health (3 credits)  
Department of Health Policy and Management, Baltimore MD

**Instructor**, AS.280.409 Health Systems Challenges from Chronic Diseases in Low- and Middle-Income Countries (Fall semester) (2013 and 2015)  
Course created by Mariana Social as part of the Gordis Teaching Fellowship  
2015 enrollment: 14 undergraduate students  
2013 enrollment: 16 undergraduate students  
Johns Hopkins University – Krieger School of Arts and Sciences (4 credits)

**Co-Instructor**, Neuro-Psychiatry I (Universidade Luterana do Brasil School of Medicine)  
Enrollment in 2008: 60 medical students  
Enrollment in 2007: 60 medical students  
Enrollment in 2006: 60 medical students

**Co-Instructor**, Neuro-Psychiatry II (Universidade Luterana do Brasil School of Medicine)  
Enrollment in 2008: 60 medical students  
Enrollment in 2007: 60 medical students  
Enrollment in 2006: 60 medical students

**Instructor**, Introduction to Neurology (Universidade Luterana do Brasil School of Speech Therapy)  
Enrollment in 2007: 20 speech therapy students  
Enrollment in 2006: 20 speech therapy students  
Enrollment in 2005: 20 speech therapy students

### *Other Significant Teaching*

#### **Guest Lectures - Johns Hopkins Bloomberg School of Public Health**

- PH 300.651.01 Introduction to the U.S. Health Care System. Lead instructor: Dan Polsky. Topic: U.S. Pharmaceutical Market. 2023, 2024.
- PH 550.608.11 - Problem Solving in Public Health. Lead instructors: Daniel Barnett and Joe Brodine. Topic: Addressing COVID-19 Treatment Pricing Using Problem-Solving Methodology. 2024.
- PH 309.620.01 – Managed Care and Health Insurance. Lead instructor: Jonathan Weiner. Topic: Pharmaceutical policy and coverage: PBMs and Medicare Part D. 2024.
- PH 221.610.01 - Pharmaceutical and Supply Chain Management: Realities from the Field. Lead instructor: Maria Eng. Topic: Pharmaceutical pricing policies in low- and middle-income countries with case studies on US and Brazil. 2024.

- PH 221.652.01- Financing Health Systems for Universal Health Coverage. Lead instructor: Krishna Rao. Topic: Pharmaceutical pricing mechanisms with case study: US. 2024.
- PH 309.670.01 - Comparative Health insurance. Lead instructor: Yang Wang. Topic: Health Systems in Low- and Middle-Income Countries. 2024.
- PH 300.610.01 Public Health Policy (MPH summer program). Lead instructor: Josh Sharfstein. Lecturer on Pharmaceutical Pricing and Policy. 2024, 2023, 2022, 2021, 2020, 2019, 2018.
- PH 550.608.19 Problem Solving in Public Health. Lead instructor: Daniel Barnett. Lecturer on Comparative Health Insurance. 2019.
- PH 223.667.11 Chronic Diseases in Low and Middle Income Countries: Prevalence and Epidemiology (Summer Institute in Tropical Medicine and Public Health). Lead instructor: Will Checkley. Lecturer in the module of brain disorders. In-person lecturer: 2022, 2019, 2018, 2017, 2016, 2015. Online lecturer: 2021, 2020.
- PH 313.861.01 Public Health Economics Seminar. Lead instructor: Jeromie Ballreich. Lecturer on Drug Coverage. 2017.
- PH 313.793.11 Extended Exercises in Cost Effectiveness (Summer Institute on Health Policy and Management). Main instructor: Greg De Lissovoy. Lectures: Framing the study; Model parameters; and Measures of "effect." 2015.

### **Teaching Assistant - Johns Hopkins Bloomberg School of Public Health**

2015-2016

- 300.610.01 Public Health Policy (4 credits)
- 309.670.01 Comparative Health Insurance (3 credits)
- 313.793.11 Extended Exercises in Cost Effectiveness (2 credits)

2014-2015

- 380.756.01 Poverty, Economic Development, and Health (4 credits)
- 309.670.01 Comparative Health Insurance (3 credits)

2013-2014

- 551.607.01 Pharmaceuticals Management for Under-Served Populations (3 credits)
- 221.617.01 Behavioral Economics in Health Decisions (2 credits)

2012-2013

- 140.621.01 Statistical Methods in Public Health I (4 credits)
- 140.622.01 Statistical Methods in Public Health II (4 credits)
- 221.647.01 Comparative Evaluation for Health Policy in International Health (3 credits)
- 221.652.01 Health Financing in Low and Middle Income Countries (3 credits)
- 313.632.01 Economic Evaluation III (3 credits)
- 221.617.01 Behavioral Economics in Health Decisions (2 credits)

## RESEARCH GRANT PARTICIPATION

### Current Funding

Agency: Johns Hopkins University NEXUS Awards

Grant title: The Johns Hopkins Drug Supply Chain Data Dashboard: Improving Data Transparency and Increasing Resiliency in the U.S. Pharmaceutical Supply Chain

Principal Investigator: Mariana Socal (BSPH)

Coinvestigators: Jeromie Ballreich (BSPH), Gerard Anderson (BSPH), Maqbool Dada (CBS), Tinglong Dai (CBS), Jeremy Greene (SOM), Josh Sharfstein (BSPH)

Level of funding: \$300,000

Dates: 2024-2025

Agency: Hopkins' Economics of Alzheimer's Disease & Services (HEADS) Center

Grant title: Mail order versus retail pharmacy use among Medicare Part D beneficiaries with dementia.

Principal Investigator: Mariana Socal

Level of Funding: \$25,000

Dates: 2023-2024

Agency: California Department of Health Care Access and Information (CA-HCAI)

Grant Title: CalRx Research and Data Support Services

Principal Investigator: Mariana Socal

Level of Funding: \$150,000

Dates: 2023-2026

### Completed Research Support

Agency: The Commonwealth Fund

Grant Title: How might Part D Plans respond to the Inflation Reduction Act?

Principal Investigator: Jeromie Ballreich (Socal: Co-Investigator)

Level of Funding: \$49,478

Dates: 2023-2024

Agency: Arnold Ventures

Grant title: Policy Options that Maximize Access to and Affordability of Prescription Drugs

Principal Investigator: Gerard Anderson (Socal: Project manager)

Level of funding: \$3,586,034

Dates: 2019-2024

Investigate the effects of drug pricing on the use of other (non-pharmaceutical) healthcare services, medication use patterns, treatment safety, and effectiveness.

Agency: Hopkins Business of Health Initiative

Grant Title: Waste-Free Formularies: Developing a tool to identify savings opportunities from

substituting high cost drugs with less expensive but clinically equivalent alternatives

Principal Investigator: Mariana Socal

Level of Funding: \$18,000

Dates: 2021-2023

Develop an automatic tool that can identify price outliers within specific therapeutic classes of interest, helping plan sponsors identify potential sources of wasteful spending in their formularies.

Agency: The Commonwealth Fund

Grant title: Mail Order Pharmacies in Medicare Part D

Principal Investigator: Mariana Socal

Level of Funding: \$85,000

Dates: 2021-2022

Investigate dispensing practices in mail order pharmacies as compared to retail pharmacies in Medicare Part D

Agency: Arnold Ventures

Grant title: Lowering Drug Prices By Phasing Out Rebates

Principal Investigator: Gerard Anderson (Socal: Co-principal investigator)

Level of Funding: \$700,000

Dates: 2018-2021

Implement strategies to reduce wasteful spending on pharmaceuticals.

Agency: ERIC - The ERISA Industry Committee

Grant title: Shifting Biologics Utilization Towards Biosimilars: How Much Can Employers Save?

Principal Investigator: Mariana Socal

Level of Funding: \$125,000

Dates: 2019-2020

Investigate patterns of biologics and biosimilar utilization among large self-insured employers, calculating savings to plan sponsors and patients.

Agency: Laura and John Arnold Foundation

Grant title: Policy Options that Maximize Access to and Affordability of Prescription Drugs

Principal Investigator: Gerard Anderson (Socal: investigator)

Level of funding: \$3,586,034

Dates: 2016-2019

Investigate the effects of drug pricing on the use of other (non-pharmaceutical) healthcare services, medication use patterns, treatment safety, and effectiveness.

Agency: NIH Grant P30 AG024361 & Princeton University Center for the Demography of Aging  
Grant title: An exploratory study of the occurrence of pharmaceutical-induced aging symptoms in the United States and in Brazil

Principal Investigator: Joao Biehl (Socal: co-principal investigator)

Level of funding: US\$70,000

Dates: 2011-2012

## ACADEMIC SERVICE

### *Division and/or Department*

2024 – PhD comprehensive qualifying exam grading committee, Health Policy and Management  
2014-2015 International Health Departmental representative, JHSPH Student Assembly

### *School*

2021-2021 Member of Adhoc Faculty Development Committee to review the request for promotion  
of Andres Vecino Ortiz to associate scientist, Department of International Health, JHSPH  
2013-2016 Founder and President, Chronic Diseases & Aging Initiative, JHSPH Student Group  
2016-2016 Student Representative, JHSPH Ethics Board  
2014-2015 Member, Quality of Life Committee, JHSPH Student Assembly

### *University*

2015-2016 Mentor, JHU Public Health Connection Program

## PRESENTATIONS

### *International Scientific Meetings*

2024

**Social, MP.** Panelist. Panel “The Inflation Reduction Act: Possible Impacts.” Presentation Title:  
Potential Impact of Drug Shortage Exemptions on Medicare Part D Inflation Rebates. American  
Society of Health Economists (ASHEcon) Annual Conference. San Diego, CA. June 19, 2024  
(panelist in oral presentation)

**Social MP,** Crane M, Anderson GF. Characteristics and Global Manufacturing of Generic Active  
Pharmaceutical Ingredients Linked to Drug Shortages in the United States. AcademyHealth Annual  
Research Meeting (ARM). Baltimore, MD. June 29-July 02, 2024. (Presenting author, poster)

**Social MP,** Ballreich J, Wang Y, Crane M, Anderson GF. Potential Impact of Drug Shortage  
Exemptions on Medicare Part D Inflation Rebates. AcademyHealth Annual Research Meeting  
(ARM). Baltimore, MD. June 29-July 02, 2024. (Presenting author, poster)

**Social MP,** Bai G, Anderson GF. Mail Order Pharmacy Use Grew in Medicare Part D 2014-2019,  
Offering Savings to Plans but Not to Beneficiaries. AcademyHealth Annual Research Meeting  
(ARM). Baltimore, MD. June 29-July 02, 2024. (Presenting author, poster)

Odouard I, Ballreich J, **Social MP.** Medicaid Spending and Utilization of Gene and RNA Therapies  
for Rare Inherited Conditions. AcademyHealth Annual Research Meeting (ARM). Baltimore, MD.  
June 29-July 02, 2024. (poster)

Makell J, Ballreich J, Bai G, Anderson GF, **Social MP.** Characteristics of Medicare Part D  
Beneficiaries with Alzheimer’s Disease and Related Dementias (ADRD) Using Mail Order  
Pharmacies. AcademyHealth Annual Research Meeting (ARM). Baltimore, MD. June 29-July 02,  
2024. (poster)

2023

**Socal, MP**, Panelist. Panel “Potential Implications of the Inflation Reduction Act on Drug Pricing, Access and Innovation: Informing Policy Makers.” American Society of Health Economists (ASHEcon) Annual Conference. St. Louis, MO. June 2, 2023 (panelist in oral presentation)

2022

**Socal, MP**, Discussant. Paper “The Effects of Physician-Pharmacy Integration: Evidence from Oral Oncology Drugs” by Pragya Kakani, American Society of Health Economists (ASHEcon) Annual Conference. Austin, TX. June 29, 2022 (discussant in oral presentation)

**Socal, MP**, Proctor C, DiStefano M, Gibbons JB, Hsu J, Alexander CA, Anderson GF. “Manufacturer-Sponsored Drug Coupons Support Insulin Product Line Extensions.” American Society of Health Economists (ASHEcon) Annual Conference. Austin, TX. June 28, 2022 (oral presentation)

Anderson K, DiStefano M, Liu A, Mattingly TJ, **Socal, MP**, Anderson GF. “Incorporating Added Therapeutic Benefit into Medicare Payment for Expensive Part B Drugs.” American Society of Health Economists (ASHEcon) Annual Conference. Austin, TX. June 29, 2022 (oral presentation)

2021

**Socal MP**, Bai G, Long J, Anderson GF. Examining Branded Multisource Drugs Dispensed in the Medicare Part D Program: Frequency of Branded Dispensing, Main Drivers, and Drug Characteristics. Academy Health National Health Policy Conference. (virtual conference) June 14-17, 2021. (poster)

**Socal MP**, Fraker JH. Manufacturer-Sponsored Programs for Access to Insulin in the COVID-19 Pandemic: How Well Are They Addressing New Patient Needs? Academy Health National Health Policy Conference. (virtual conference) June 14-17, 2021. (poster)

2020

Wormser B, **Socal MP**, Anderson GF. Coverage and Coinsurance for Guideline-Recommended Inhalers for Chronic Obstructive Pulmonary Disease in Medicare Part D Plans: a Cross-Sectional Study. Academy Health National Health Policy Conference. (Washington, DC) February 10-11, 2020. (poster)

2019

**Socal MP**, Yehia F, Bai G, Anderson GF. Therapeutic Class Coverage across Medicare Part D Drug Plans. Academy Health Research Meeting (ARM). (Washington, DC) June 03-06, 2019. (poster)

2018

**Socal MP**. “Formulary Options to Control Drug Pricing in Medicare Part D.” Association for

Public Policy Analysis & Management (APPAM) Fall research Conference. (Washington, DC) November 08-10, 2018 (oral presentation)

**Socal MP**, Patel P, Parasrampur S, Padula W, Anderson GF. “Examining the Target Population of Orphan Drugs: Are Drugs Exceeding the Intended Purposes of the Orphan Drug Act?” International Society of Pharmacoeconomics and Outcomes Research (ISPOR) (Baltimore, MD), 19-23 May 2018. (poster)

2017

**Socal MP**, Anderson G. “Individual and Community-Level Determinants of Polypharmacy among Brazilian Eldery.” International Conference on Pharmacoepidemiology and Therapeutic Risk Management. (Montreal, Canada) Aug 26-30, 2017 (poster)

Alexander GC, Ballreich J, **Socal MP**, Karmarkar T, Trujillo A, Greene J, Sharfstein J, Anderson G. Reducing branded prescription drug prices: A review of policy options. International Conference on Pharmacoepidemiology and Therapeutic Risk Management. (Montreal, Canada) Aug 26-30, 2017 (poster)

2016

**Socal MP**, Anderson G. “Health Systems Determinants of Pharmaceutical Use among Brazilian Eldery”. 4th Global Symposium on Health Systems Research. (Vancouver, Canada) Nov 14-18 2016 (poster)

2015

**Socal MP**, Trujillo A. " Chronic Illness and Late-Life Cognitive Decline". Research on Aging Showcase. Johns Hopkins Center on Aging and Health. (Baltimore, USA) May 15 2015 (poster)

2013

**Socal MP**. “Access and Utilization of Medicines: The Role of Health Technology Assessment from a Health Systems Perspective” Pharmacogenomics: From Molecules to Medicine. (Engelberg, Switzerland) July 09-13 2013 (oral presentation)

2012

**Socal MP**, Uribe MV, Rao KD. “Serving all and serving well? The Brazilian universal healthcare system and the challenge of the equitable allocation of healthcare resources”. 2nd Global Symposium on Health Systems Research. (Beijing, China) 31 Oct- 3 Nov 2012 (oral presentation)

**Socal. MP**. “Measuring The Gap Between Demand and Access to Medicines in The Brazilian Public Healthcare System”. 9th HTAi Health Technology Assessment International Annual Meeting 2012. HTA in Integrated Care for a Patient-Centered System. (Bilbao, Spain) (oral presentation)

**Socal. MP**. “Estimating Access to Health Services in Brazil Through a Market Frontier Analysis”. 9th HTAi Health Technology Assessment International Annual Meeting 2012. HTA in Integrated Care for a Patient-Centered System. (Bilbao, Spain) (poster)

2010

Picon PD, Gonzalez RS, Picon RV, Terra CD, Gertner A, Barbosa J, **Socal M**, Gonçalves J, Petryna A, Biehl J. “Court decisions and pharmaceutical policy in Brazil: Odds for the patients and

for the state”. 7th HTAi - Health Technology Assessment International 2010 (Dublin, Ireland) (poster)

Picon PD, Gonzalez RS, Picon RV, Terra CD, Gertner A, Barbosa J, Socal M, Jardim PM, Petryna A, Biehl J. “The impact of plaintiff economic status on access to the legal system: Suing the state of medicines in Rio Grande do Sul, Brazil.” 7th HTAi - Health Technology Assessment International 2010 (Dublin, Ireland) (poster)

2009

An analysis of claims of irreparable harm in lawsuits for access to medicines in the state of Rio Grande do Sul, Brazil. 6th HTAi—Health Technology Assessment International 2009 (Singapore, Singapore) (poster)

Demanding Treatment Access through Regular Administrative Pathways and through Lawsuits in Brazil. 6th HTAi—Health Technology Assessment International 2009 (Singapore, Singapore) (poster)

Claiming the Right to Medicines in Brazil through Public and Private Doctors and Lawyers: A Pilot Study. 6th HTAi—Health Technology Assessment International 2009 (Singapore, Singapore) (poster)

2008

Peer-review of Medical Prescription of Pramipexole in the Public Health System in the South of Brazil: Evidence of an Irrational Use of Dopaminergic Agonists for Parkinson’s Disease. 5th HTAi—Health Technology Assessment International 2008 (Montréal, Canada) (poster)

Progressive Multifocal Leuko-Encephalopathy Induced by Monoclonal Antibodies—A Systematic Review of Literature: Preliminary Data. 5th HTAi—Health Technology Assessment International 2008 (Montréal, Canada) (poster)

2007

Implementation of Brazilian Guidelines for Botulinum Toxin: A Three-Year Follow-up of a Cost-reduction Strategy in the Public Health System of Rio Grande do Sul, Brazil. 4th HTAi - Health Technology Assessment International 2007 (Barcelona, Spain) (oral presentation)

2000

Cunha GB, Silva AR, Dieder AL, Wolf AL, Zambrano C, Silva FF, Pretto I, Oliveira J, Silva PF, Socal MP, Margis R, Weissheimer R, Rotta NT. Prevalence of Cocaine Prenatal Exposure Detected as Benzoilecgonine in Newborns VIII Congreso Anual de la Academia Iberoamericana de Neurología Pediátrica. (Spain) – abstract available in: *Comunicaciones Revista de Neurologia, Espanha*, v. 31, n. 3, p. 228-228, 2000.

### *Invited Lectures and Seminars*

2022

University of Pennsylvania Perelman School of Medicine Immersive Advocacy Summer Course—“Expert Panel: Prescription Drug Affordability Board Legislation” Online Event – July 12, 2022



2018

Johns Hopkins University  
Internal Medicine Residency Program, Urban Health Noon Conference Series  
Lecture: Health Policy and Prescription Drug Pricing

2014

Johns Hopkins Bloomberg School of Public Health  
Course: Brasilia Without Borders Executive Program in Public Leadership.  
Main instructor: Carlos Castillo  
Lecture: Between Policy and Justice: Access to Medicines in Brazil

### **ADDITIONAL INFORMATION**

#### *Personal statement of research and practice goals, objectives and impact*

Affordable, sustainable, and qualified access to medicines is a challenge to countries worldwide, especially as populations get older and chronic diseases become more prevalent. The appropriate and sustainable use of medicines, an issue that cuts across all areas of medicine and medical care, is of great public health relevance globally. The United States faces the simultaneous challenge of ensuring affordable, safe, and sustainable access to life-saving pharmaceutical treatments while needing to cut back on wasteful drug spending through improved product selection and reducing the inappropriate use of polypharmacy, all while maintaining incentives for pharmaceutical innovation. I am committed to researching ways to safeguard sustainable, affordable, and appropriate access to pharmaceutical treatments for populations in the United States and around the world, especially those who are most vulnerable, disenfranchised, and underserved - such as older adults with disabilities, and latinx populations - while protecting the incentives to ensure that groundbreaking new therapies continue to be developed and become available to those who need them. I am also committed to translating my research findings to actionable policies through public engagement at the US federal and state levels, as well as the global level through my service to the World Health Organization. Last but not least, I am committed to training the next generation of public health scholars and leaders through teaching and mentoring and to expanding the diversity and inclusion in the representation in this field.

#### *Keywords (for sorting)*

Pharmaceutical policy, access to medicines, drug pricing, drug safety, treatment appropriateness, health systems, health insurance, chronic diseases, low- and middle-income countries, Medicare, employment-sponsored health insurance, pharmacy benefit managers, prescription drug benefit.